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A B S T R A C T
Background
The dystrophinopathies include Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and X-linked dilated
cardiomyopathy (XLDCM). In recent years, co-ordinated multidisciplinary management for these diseases has improved the quality
of care, with early corticosteroid use prolonging independent ambulation, and the routine use of non-invasive ventilation signficantly
increasing survival. The next target to improve outcomes is optimising treatments to delay the onset or slow the progression of cardiac
involvement and so prolong survival further.
Objectives
To assess the effects of interventions for preventing or treating cardiac involvement in DMD, BMD, and XLDCM, using measures of
change in cardiac function over six months.
Search methods
On 16 October 2017 we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE and Embase, and on
12 December 2017, we searched two clinical trials registries. We also searched conference proceedings and bibliographies.
Selection criteria
We considered only randomised controlled trials (RCTs), quasi-RCTs and randomised cross-over trials for inclusion. In the Discussion,
we reviewed open studies, longitudinal observational studies and individual case reports but only discussed studies that adequately
described the diagnosis, intervention, pretreatment, and post-treatment states and in which follow-up lasted for at least six months.
Data collection and analysis
Two authors independently reviewed the titles and abstracts identified from the search and performed data extraction. All three authors
assessed risk of bias independently, compared results, and decided which trials met the inclusion criteria. They assessed the certainty of
evidence using GRADE criteria.
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Main results
We included five studies (N = 205) in the review; four studies included participants withDMDonly, and one study included participants
with DMD or BMD. All studied different interventions, and meta-analysis was not possible. We found no studies for XLDCM. None
of the trials reported cardiac function as improved or stable cardiac versus deteriorated.
The randomised first part of a two-part study of perindopril (N = 28) versus placebo (N = 27) in boys with DMD with normal heart
function at baseline showed no difference in the number of participants with a left ventricular ejection fraction (LVEF%) of less than
45% after three years of therapy (n = 1 in each group; risk ratio (RR) 1.04, 95% confidence interval (CI) 0.07 to 15.77). This result
is uncertain because of study limitations, indirectness and imprecision. In a non-randomised follow-up study, after 10 years, more
participants who had received placebo from the beginning had reduced LVEF% (less than 45%). Adverse event rates were similar
between the placebo and treatment groups (low-certainty evidence).
A study comparing treatment with lisinopril versus losartan in 23 boys newly diagnosed with Duchenne cardiomyopathy showed that
after 12 months, both were equally effective in preserving or improving LVEF% (lisinopril 54.6% (standard deviation (SD) 5.19),
losartan 55.2% (SD 7.19); mean difference (MD)−0.60% CI−6.67 to 5.47: N = 16). The certainty of evidence was very low because
of very serious imprecision and study limitations (risk of bias). Two participants in the losartan group were withdrawn due to adverse
events: one participant developed an allergic reaction, and a second exceeded the safety standard with a fall in ejection fraction greater
than 10%. Authors reported no other adverse events related to the medication (N = 22; very low-certainty evidence).
A study comparing idebenone versus placebo in 21 boys with DMD showed little or no difference in mean change in cardiac function
between the two groups from baseline to 12 months; for fractional shortening the mean change was 1.4% (SD 4.1) in the idebenone
group and 1.6% (SD 2.6) in the placebo group (MD −0.20%, 95% CI −3.07 to 2.67, N = 21), and for ejection fraction the mean
change was −1.9% (SD 9.8) in the idebenone group and 0.4% (SD 5.5) in the placebo group (MD−2.30%, 95% CI −9.18 to 4.58,
N = 21). The certainty of evidence was very low because of study limitations and very serious imprecision. Reported adverse events
were similar between the treatment and placebo groups (low-certainty evidence).
A multicentre controlled study added eplerenone or placebo to 42 patients with DMD with early cardiomyopathy but preserved left
ventricular function already established on ACEI or ARB therapy. Results showed that eplerenone slowed the rate of decline of magnetic
resonance (MR)-assessed left ventricular circumferential strain at 12 months (eplerenone group median 1.0%, interquartile range (IQR)
0.3 to −2.2; placebo group median 2.2%, IQR 1.3 to −3.1%; P = 0.020). The median decline in LVEF over the same period was
also less in the eplerenone group (−1.8%, IQR −2.9 to 6.0) than in the placebo group (−3.7%, IQR −10.8 to 1.0; P = 0.032). We
downgraded the certainty of evidence to very low for study limitations and serious imprecision. Serious adverse events were reported
in two patients given placebo but none in the treatment group (very low-certainty evidence).
A randomised placebo-controlled study of subcutaneous growth hormone in 16 participants with DMD or BMD showed an increase
in left ventricular mass after three months’ treatment but no significant improvement in cardiac function. The evidence was of very low
certainty due to imprecision, indirectness, and study limitations. There were no clinically significant adverse events (very low-certainty
evidence).
Some studies were at risk of bias, and all were small. Therefore, although there is some evidence fromnon-randomised data to support the
prophylactic use of perindopril for cardioprotection ahead of detectable cardiomyopathy, and for lisinopril or losartan plus eplerenone
once cardiomyopathy is detectable, this must be considered of very low certainty. Findings from non-randomised studies, some of
which have been long term, have led to the use of these drugs in daily clinical practice.
Authors’ conclusions
Based on the available evidence from RCTs, early treatment with ACE inhibitors or ARBs may be comparably beneficial for people
with a dystrophinopathy; however, the certainty of evidence is very low. Very low-certainty evidence indicates that adding eplerenone
might give additional benefit when early cardiomyopathy is detected. No clinically meaningful effect was seen for growth hormone or
idebenone, although the certainty of the evidence is also very low.
P L A I N L A N G U A G E S U M M A R Y
Preventing and treating heart complications inDuchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy
Review question
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What are the effects of treatments used to prevent or treat heart complications in Duchenne muscular dystrophy (DMD), Becker
muscular dystrophy (BMD), and X-linked dilated cardiomyopathy (XLDCM)?
Background
The protein dystrophin is essential for muscles to work normally. DMD, BMD and XLDCM are inherited muscle diseases caused by
changes in the gene that controls production of dystrophin. People with these conditions develop muscle wasting and weakness. In the
heart, a lack of dystrophin causes muscle damage and scarring, which over time causes the heart to fail. Eventually the heart chambers
enlarge, which is known as dilated cardiomyopathy. This serious complication can be a cause of death. There are a number of possible
treatments for heart problems in these muscle conditions. One option is to reduce the workload of the heart with drugs that lower
blood pressure (angiotensin-converting-enzyme inhibitors, ACE inhibitors) or slow the heart rate (beta blockers or ivabradine). Another
approach is to reduce muscle damage with antioxidants (e.g. idebenone) or medicines that target inflammation (e.g. corticosteroids).
Recently, drugs that increase dystrophin have been developed, including ataluren and eteplirsen.
Study characteristics
Cochrane Review authors collected all relevant studies to answer their review question. They searched for trials looking to prevent or
treat heart complications in people with DMD, BMD or XLDCM. They limited the review to trials that randomly assign participants
to one treatment or another, which usually provide the best evidence. They identified five small trials, with a total of 205 participants.
- A three-year study of perindopril versus placebo (an inactive pill) to prevent heart complications in 57 boys with DMD. The
randomised trial was followed by two years of open treatment, then a follow-up study of 10 years when all children received perindopril.
- A one-year study of lisinopril versus losartan in 23 patients with DMD and newly diagnosed heart complications.
- A one-year study of idebenone versus placebo in 21 boys with DMD, which the manufacturer funded.
- A one-year study of eplerenone versus placebo in 42 patients with DMDwho already had heart complications, which themanufacturer
partly funded.
- A three-month study of growth hormone versus placebo in 10 patients with DMD or BMD.
Key results and certainty of the evidence
Based on the available evidence from RCTs, early treatment with ACE inhibitors or angiotensin receptor blockers (ARBs) may help
people with DMD. In boys with early heart involvement, the effect of ACE inhibitor and ARBmay be equivalent; however, the evidence
is very uncertain. Findings from non-randomised studies, some of which have been long term, have led to the use of these drugs in
daily clinical practice. Very low-certainty evidence indicates that adding eplerenone might give additional benefit in DMD when early
cardiomyopathy is detected. We did not see a clinically meaningful effect for growth hormone or idebenone in the studies examined,
although the certainty of the evidence was also very low. The trials provided only low or very low-certainty evidence on side effects.
Overall, the numbers of patients in each of these studies was small, and some studies had limitations that might have affected the
results, so we are very uncertain about the results.
The evidence is current to October 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Prophylactic perindopril (2 mg to 4 mg daily) versus placebo in DMD
Patient or population: boys with DMD, normal cardiac examinat ion and LVEF > 55% at baseline
Setting: 10 clinics in France
Intervention: prophylact ic perindopril (2 mg to 4 mg daily)
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with prophylactic
perindopril (2 mg to 4
mg daily)
Change in cardiac func-
t ion: number of pat ients
with EF < 45%
Assessed with: ra-
dionuclide ventriculog-
raphy
Follow-up: 36 months
Study populat ion RR 1.04
(0.07 to 15.77)
57
(1 RCT)
⊕©©©
Very lowa
Results of an open-la-
bel extension study are
not shown here. See
text
34 per 1000 36 per 1000
(2 to 544)
Size of metabolically
abnormal areas of my-
ocardium
Not reported
Improvements in qual-
ity of lif e measures
Not reported
Adverse events
Follow-up: 36 months
Study populat ion RR 1.16
(0.78 to 1.72)
57
(1 RCT)
⊕⊕©©
Lowb
-
586 per 1000 680 per 1000
(457 to 1000)
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*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; DMD: Duchenne muscular dystrophy; LVEF: lef t ventricular eject ion f ract ion; RCT : randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aWe downgraded the certainty of the evidence three t imes as the method of randomisat ion was not clear (study lim itat ions),
the study was small (imprecision), and the boys in this trial started phase 1 of the trial when their cardiac funct ion was
normal (indirectness). The randomised phase of the study lasted three years, not long enough in this phase of the disease
for data to determ ine the ef fect on decline in cardiac funct ion.
bWe downgraded the certainty of the evidence twice as the method of randomisat ion was not clear (study lim itat ions) and the
study was small (imprecision).
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B A C K G R O U N D
Dystrophinopathies are a group of X-linked inherited degenera-
tive muscle disorders, including Duchenne muscular dystrophy
(DMD), Becker muscular dystrophy (BMD) and X-linked di-
lated cardiomyopathy (XLDCM). These three allelic conditions
are caused by deletions, duplications or missense mutations in
the dystrophin gene at Xp21.2 (Gardner 1995; Koenig 1989;
Malhotra 1988; Muntoni 1997). The typical cardiac abnormality
found in all dystrophinopathy patients is dilated cardiomyopathy.
DMD is the most severe of these disorders and has an incidence of
1:3500 to 1:6000 live male births (Mendell 2012); muscle biopsy
shows dystrophic changes and complete or almost complete ab-
sence of the sarcolemmal protein dystrophin. The condition usu-
ally presents with muscle weakness by 5 years of age. Without
treatment, all affected children lose the ability to walk by their
13th birthday. Once the child is wheelchair dependent, contrac-
tures and scoliosis traditionally develop rapidly - often requiring
surgery. Premature death fromuntreated respiratory or cardiac fail-
ure occurs on average at 18.5 years (Emery 2003). In recent years,
the natural history of the condition has been improved by greater
integration of care through multidisciplinary teams. Two devel-
opments in particular have led to incremental improvements in
survival: routine use of glucocorticoid steroids to improve muscle
strength and prolong independent ambulation (Matthews 2016),
and routine deployment of non-invasive nocturnal ventilation us-
ing mask bilevel positive airway pressure ventilation (BIPAP) to
improve symptoms and delay death from respiratory failure to a
mean of 25 years (Eagle 2002). Cardiac involvement culminat-
ing in dilated cardiomyopathy with congestive cardiac failure or
ventricular arrhythmias remains a key contributor to premature
death in DMD. In the absence of cardioactive therapies, the nat-
ural history of cardiac involvement has not changed despite the
other significant improvements in physical and respiratory man-
agement and has become a more common cause of death with
40% to 50% of DMD patients dying as a direct consequence of
cardiac involvement (Eagle 2002; Muntoni 2003).
BMD was first described in 1955 (Becker 1955). The condition
is less common than DMD, with a reported incidence of between
1:14,000 and 1:18,000 males (Bushby 1991). BMD resembles
DMD, but it is milder with a slower progression of muscle weak-
ness because the reading frame of the gene is preserved. This re-
sults in the production of a dystrophinmolecule which has a lower
molecular weight and which is less abundant than normal. There
is a broad spectrum of clinical severity in BMD, with onset of
symptoms occurring from early childhood to as late as the sixth
decade (Emery 1976; Quinlivan 1995). Only 10% of Becker’s
original series of patients, for example, lost independent ambula-
tion before the age of 40 years, and none lost ambulation before
the age of 16 years (Becker 1955). As with DMD, life expectancy
can be reduced by respiratory insufficiency and disproportionately
by cardiomyopathy.
XLDCM is a rapidly-progressive cardiomyopathy occurring in
teenage boys caused by a deletion in exon 1 of the dystrophin gene.
Skeletal muscles are not usually involved (Towbin 1993). With-
out cardiac transplantation, death occurs within one to two years
of the onset of symptoms. In some cases the distinction between
XLDCM and a mild variant of BMD can be difficult.
Female carriers of DMD and BMD have been shown to be at in-
creased risk of developing dilated cardiomyopathy (Bushby 1993;
Hoogerwaard 1999; Kamamura 1990; Lane 1980; Nolan 2003),
although the impact on survival is uncertain (Holloway 2008).
Description of the condition
Dystrophin plays a crucial role in force transduction between cell
membranes and the intracellular contractile elements of skeletal
and cardiac muscle. When absent or deficient, cell membranes be-
come highly vulnerable to damage, swamping natural repairmech-
anisms, leading to cell death and tissue fibrosis (Danialou 2001;
Menke 1991). Typically the first detectable sign of this process
in the heart is found on the electrocardiogram (ECG) with the
development of Q waves in the lateral (I and AVL) or inferolateral
and apical (II, III, aVF, V5-V6) leads (Hoogerwaard 1997; Nigro
1990; Nigro 1995), increased voltages in the right precordial leads
(V1-3) (Nikolic 1998), abnormalities in repolarisation (inverted
or dysmorphic T waves), and increase in the so-called ’cardiomy-
opathic index’ (the ratio of QT-interval (ms)/end-of-P wave to
QRS onset (ms) (Nigro 1995). These changes can be seen from the
age of 6 years in DMD and are almost universal by 12 years (Bies
1992). Although defining the end of dysmorphic T waves may
be difficult, some have correlated QT-prolongation on the surface
ECGwith increased incidence of sudden death (Nigro 2002). The
time-course and extent of ECG abnormalities are more variable
in BMD. In both DMD and BMD, fully evolved ECG changes
precede the development of echocardiographically detectable left
ventricular dysfunction by many years and thus have no clinical
correlation with the degree of cardiomyopathy (Heymsfield 1978)
Although limited in sensitivity and operator dependent, echocar-
diography is the preferred initial screening method for detecting
cardiac involvement in the dystrophinopathies (Nigro 1990). This
is because it is readily available, easily repeatable and inexpen-
sive. The first sign of ventricular systolic dysfunction is segmental
left ventricular systolic dysfunction, typically found in the pos-
tero-basal segments (Miyoshi 1991; Nigro 1983; Tanaka 1979).
Without treatment the extent of abnormality spreads to affect
the whole ventricle over time, culminating in chamber dilatation
and global systolic dysfunction (Backman 1992; Corrado 2002;
De Kermadec 1994; Ferlini 1999; Finsterer 2003; Olfors 1994;
Perloff 1984; Takenaka 1993). About 90% of male patients with
DMD develop a severe progressive form of cardiac involvement
(Heymsfield 1978; Mukoyama 1987), with 20% to 30% hav-
ing evidence of left ventricular impairment by 10 years of age
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(Backman 1992; Finsterer 2003). When deploying more sensi-
tive imaging techniques, such as tissue-Doppler echocardiography
(Meune 2004; Mori 2007), 2D-strain deformation imaging, car-
diac magnetic resonance imaging (CMRI), single photon emis-
sion tomography (SPECT), positron emission tomography (PET)
or 31phosphorous magnetic resonance spectroscopy (31PMRS),
abnormalities in left ventricular function are evident in an even
larger proportion of patients in their teens (Griffin 2001; Perloff
1984; Quinlivan 1996; Silva 2007; Yamamoto 1988).
In BMD the incidence of cardiac involvement, its age of onset and
implications for prognosis are more variable (Angelini 1996; De
Visser 1992;Melacini 1996; Steare 1992). Although some 90% of
patients with BMD show ECG abnormalities similar to those seen
in DMD, only 65% develop left ventricular systolic dysfunction
when assessed by echocardiography. However, in some the severity
of cardiac involvement may be disproportionate to skeletal muscle
weakness and may even be the presenting feature of the condition
(Sakata 1990; Steare 1992). In such cases cardiac involvement be-
comes the determinant of long-term prognosis (Ishigaki 1997).
Best estimates from longitudinal series suggest that cardiac involve-
ment contributes directly to death in up to 50% of male patients
with BMDcomparedwith 20%ofDMDpatients (Angelini 1996;
Hoogerwaard 1997; Melacini 1996; Muntoni 2003; Olfors 1994;
Steare 1992). However, in recent years with improved care, par-
ticularly the use of domiciliary ventilatory support, unpublished
estimates of end-stage dilated cardiomyopathy as a cause of death
in DMD are between 40% to 50%.
Some DMD and BMD patients develop a sinus tachycardia un-
related to respiratory failure or other cardiac abnormalities, which
is usually attributed to sympathovagal imbalance in cardiac au-
tonomic function (Lanza 2001). Persistent, inappropriate sinus
tachycardia may accelerate the development of cardiomyopathy or
simply be a sign of subclinical cardiac involvement (Kwon 2012).
CMRI can find evidence of left ventricular non-compaction in
a high proportion of DMD patients before any reduction in left
ventricular function is identified (Stabile 2013). Atrial natriuretic
peptide (ANP) and brain natriouretic peptide (BNP), biomarkers
for cardiac impairment, are not sensitive markers for early systolic
impairment in DMD; however, once the fractional shortening
(FS) is less than 15%, these biomarkers increase and are associated
with poor prognosis (Mori 2002).
Complete atrioventricular (AV) block is thought to be uncom-
mon in the dystrophinopathies, but there have been a number of
case reports of patients with DMD requiring permanent pacing
(Andrikopoulos 2013; Fayssoil 2008; Kono 2015; Kuru 2012).
Focal areas of fibrosis in the conducting system have been de-
scribed in BMD postmortem studies (Donofrio 1989). Abrupt
onset of complete heart block without an escape rhythm could ac-
count for a proportion of sudden cardiac deaths at more advanced
stages of DMD. Prolongation of the QT interval has been noted
in a proportion of DMD ECGs and could increase risk of cardiac
tachyarrhythmias and sudden death (Nigro 1983). In one BMD
patient, complete AV block was reported as the presenting feature,
withmuscle weakness only developing some years later (Quinlivan
1995). Ventricular tachycardia and fibrillation have been reported
in DMD and BMD patients with established cardiomyopathy.
However, the extent to which prophylactic use of implantable de-
fibrillators would prolong survival in DMD is unknown.
Histological examination of endocardial biopsies from patients
with all types of dystrophinopathy are similar. Typical findings are
of hypertrophic cardiomyocytes with increased internal nuclei, en-
docardial and interstitial fibrosis associated with cytoplasmic lipo-
fuscinosis and focal lymphocytic infiltration, large pleomorphic
bizarre nuclei, vacuoles and focal necrosis (Casazza 1988). At post-
mortem, the pathological features of heart involvement in either
DMD or BMD are replacement of cardiac fibres with connective
tissue and extensive myocardial fibrosis (Globus 1923;Heymsfield
1978; Olfors 1994).
Description of the intervention
There are a wide range of pharmacological and non-pharmaco-
logical interventions that could potentially preserve or improve
cardiac function, alone or in combination, including:
• angiotensin converting enzyme (ACE) inhibitors, e.g.
ramipril, perindopril, captopril, lisinopril and enalapril;
• angiotensin II type I receptor (ATI1) inhibitors
(angiotensin receptor blocking agents (ARB)), e.g. losartan,
irbesartan, candesartan, and valsartan;
• beta-blockers, e.g. bisoprolol, metoprolol and carvedilol;
and sinus node slowing agents, e.g. ivabradine to slow heart rate
• diuretics, e.g. aldosterone antagonists such as
spironolactone and eplerenone; bendrofluazide; and loop
diuretics such as bumetanide and furosemide;
• calcium channel blockers, e.g. verapamil, amlodipine, and
diltiazem;
• magnesium;
• phosphodiesterase type 3 (milrinone) and type 5 inhibitors
(sildenafil and tadalafil);
• positive inotropic agents, e.g. digoxin, bypiridine
inhibitors, calcium, catecholamine agonists, and milrinone;
• drugs to treat cardiac arrhythmias, e.g. amiodarone, sotalol,
and flecainide;
• drugs which affect the vascular response to nitric oxide, e.g.
sildenafil;
• anti-coagulants e.g. warfarin, coumadin, dabigatran,
apixaban, and rivaroxaban
• drugs that alter the natural history of the disease (i.e.
improve skeletal muscle function or increase dystrophin
expression), e.g. glucocorticosteroids, idebenone, coenzyme
Q10, ataluren (PTC124), and antisense oligonucleotides for
DMD; and
• non-pharmacological interventions, such as single and dual
chamber pacemakers, cardiac resynchronisation therapy (CRT)
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pacemakers, implantable cardioverter defibrillator (ICD or CRT-
D), left ventricular assist devices (LVAD; extravascular counter-
pulsation devices), and cardiac transplantation.
How the intervention might work
We divide interventions into three subsets.
Drugs acting on the cardiovascular system
In the face of damage to the left ventricle, a variety of primitive
reflexes activate, and the heart and circulation undergo a process
of remodelling, which initially preserves cardiac output and per-
fusion to vital organs but ultimately causes the heart to progres-
sively decompensate. Several categories of drugs are used routinely
in contexts other than DMD/BMD to block these adverse adap-
tations, thus preventing this downward spiral of ventricular dys-
function.
Blocking the renin-angiotensin system by ACE inhibitors, ARBs
or renin antagonists prevents inappropriate salt and water accu-
mulation by the kidney and the directly toxic effects of excessive
angiotensin II, which include vasoconstriction, apoptosis and pro-
motion of cardiac fibrosis (Burnett 2017; Cicoira 2002; Heran
2012; Ponikowski 2016; Zannad 2000).
Blocking the effects of increased circulating endogenous cat-
echolamines and direct neural stimulation by beta-adrenergic
blockers slows the heart rate, reducing myocardial oxygen con-
sumption and peripheral vasoconstriction. These agents also pre-
vent the unhelpful down-regulation of beta adrenoreceptors in the
heart. When doses of beta-blocking drugs cannot be up-titrated
adequately, the selective sinus node slowing agent ivabradine can
be added to improve heart failure by slowing the heart rate further
(Abdel-Salam 2014; Ponikowski 2016; Swedberg 2010).
When there is evidence of fluid retentionwith overt cardiac failure,
loop diuretics promote loss of salt and water by the kidney and so
relieve symptoms of congestion and fluid overload. Loop diuretics
(e.g. furosemide and bumetanide) are used with ACE inhibitors
in this context. Spironolactone and eplerenone are weaker diuret-
ics, which importantly conserve potassium and also have an an-
tifibrotic effect on cardiac muscle (Cicoira 2002; Zannad 2000).
Positive inotropic drugs increase myocardial contractility and can
be used to support severely depressed cardiac function. However,
their symptomatic benefit is often short-lived. Type 3 phosphodi-
esterase inhibitors such as milrinone increase cardiac output at the
cost of increased myocardial work, myocardial oxygen consump-
tion and heart rate. Unless used in the context of some reversible
cause of cardiac deterioration, positive inotropic agents eventu-
ally exacerbate cardiac dysfunction and accelerate its progressive
decompensation. However, in end-stage cardiac failure in DMD/
BMD, the prognosis is so poor that these agents may offer short-
term, symptomatic palliative benefits.
Cardiac arrhythmias, such as atrial fibrillation, result in an acute
loss of atrial transport to ventricular filling and a sudden increase
in ventricular rate. This can precipitate cardiac decompensation
acutely with development of heart failure symptoms in patients
with reduced left ventricular reserve. Ventricular tachyarrhythmias
typically presentmore dramatically with unheralded acute collapse
or virtually instantaneous death in the context of asymptomatic
but advanced cardiomyopathy. Anti-arrhythmic drug therapies
other than beta-blockers have little impact on the occurrence or
severity of ventricular tachycardia or ventricular fibrillation in car-
diomyopathy of other aetiologies. In other contexts, cardioverter-
defibrillator therapy is the standard recommendation in patients
with severe left ventricular dysfunction, but not in those with New
York Heart Association (NYHA) functional class IV symptoms,
for the primary prevention of sudden cardiac death due to ven-
tricular tachyarrhythmias. An important consideration, given the
resting tachycardia in DMD, is that slowing the heart rate in pa-
tients with with dilated cardiomyopathy could potentially improve
heart function.
Patients with DMD/BMD have dramatically reduced mobility
and so are theoretically at risk of developing peripheral venous
thrombosis and pulmonary emboli (although there is a surpris-
ing dearth of published literature regarding this complication).
If small, these can occur silently, but when large they can cause
catastrophic haemodynamic collapse and sudden death - indistin-
guishable clinically from a tachy- or bradyarrhythmia. In patients
with advanced left ventricular dysfunction, blood clots can form
in either the left atrium or left ventricle and result in systemic
emboli, most frequently causing stroke. Prophylactic low-dose or
full anticoagulation can prevent venous and arterial thromboem-
bolism, respectively.
Because there is a published review of the effect of calcium antago-
nists used in DMD to improve skeletal rather than cardiac muscle
function, we will not discuss these agents further in this review
(Phillips 2008).
Non-pharmacological treatments for advanced
cardiac failure and arrhythmias
Standard dual chamber pacing is indicated in the small subgroup
of DMD/BMD patients who develop bradycardia due to sinus or
AV-nodal conduction problems. A more recent pacing indication
comes from the realisation that, in hearts with already impaired
left ventricular systolic function, the development of left bundle
branch block or a non-specifically widened QRS, causes dyssyn-
chrony of contraction and so a further reduction in left ventric-
ular function. Pacing from two sites on opposite walls of the left
ventricle narrows the abnormally widened QRS complex by facil-
itating faster and more synchronous left ventricular contraction,
optimising contraction for the same stage of cardiomyopathy. Re-
cent studies in patients with idiopathic cardiomyopathy show that
in appropriately selected patients, CRT significantly improves car-
diac function and heart failure symptoms and prolongs life. It also
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reduces hospitalisations for heart failure (Turley 2008). The role
of CRT in DMD/BMD seems limited, however, since most peo-
ple - even with advanced cardiomyopathy - do not develop QRS-
complex widening. Even in those who do, it remains speculative
whether they would respond to CRT. This is because the earli-
est and most extensively scarred segment of the left ventricle in
patients with DMD/BMD is typically epicardial in the postero-
lateral or postero-basal segments, and the lateral wall is usually
the preferred site for left ventricular lead placement to restore syn-
chrony (Bleeker 2006; Hor 2011).
Patients with established cardiomyopathy are at particular risk of
developing haemodynamically compromising ventricular tachy-
cardia or ventricular fibrillation, manifesting as sudden cardiac
death. By restoring normal rhythm from such unpredictable
events, implantable cardioverter-defibrillators have been shown to
significantly reduce the incidence of sudden cardiac death in var-
ious subsets of patients with cardiomyopathy (Cevik 2010). All
implanted cardioverter-defibrillators, except those without leads
in the heart (i.e. subcutaneous implantable cardioverter-defibrilla-
tors), also contain bradycardia pacing capabilities. The impact of
defibrillator therapy on quality of life and overall effect on survival
in DMD in particular has yet to be established (Wagner 2007).
When available, cardiac transplantation is an effective treatment
for patients with end-stage cardiomyopathy and short predicted
survival, and it could be an option for patients with BMD and
XLDCM (Wu 2010). Almost 80% of heart transplant recipients
survive for at least one year, and up to 74% survive for five years
(Fararolo 2010). However, because of the multisystem nature of
DMD and the shortage of suitable donors for all categories of pa-
tients who might benefit, cardiac transplantation is rarely consid-
ered appropriate in DMD (Papa 2017). The more recent develop-
ment and increasing availability of a range of battery-powered, left
ventricular mechanical pump support devices (e.g. left ventricular
assist device (LVAD), counter-pulsation devices) offer an alterna-
tive which may be more relevant and more widely applicable to
DMD patients with heart failure (Abraham 2014; Black 2016;
Iodice 2015; Ryan 2014).
Drugs that improve the natural history of the
condition
Corticosteroids are known to increase muscle strength in DMD
and can prolong ambulation (Matthews 2016), so they have now
become part of routine care for DMD. Their precise mechanism
of action is not known. It seems likely from non-randomised ret-
rospective cohort data that corticosteroids also modify the natural
history of cardiac involvement in DMD (Barber 2013; Schram
2013; Silversides 2003).One long-term follow-up study compared
the clinical course of deflazacort-treated DMD patients with his-
torical untreated DMD patients and demonstrated improved res-
piratory parameters and echocardiographic measures of left ven-
tricular function in the deflazacort-treated group (Biggar 2006).
Drugs to reduce oxidative stress (e.g. idebenone and coenzyme
Q10) could potentially slow the dystrophic process and have a
protective effect.
A range of drugs (e.g. ataluren (Translarna; previously known as
PTC 124); antisense oligonucleotides) and cell therapies (stem
cells and myoblast transfer and gene therapy) designed to increase
dystrophin levels or upregulate utrophin are currently under eval-
uation. If shown to be clinically effective in improving skeletal
muscle function, research would need to independently establish
the effect of these potential therapies on the heart. It is already
clear, however, that some therapies shown to be of benefit to skele-
tal muscle in animal models of DMD do not penetrate the heart
(Aartsma-Rus 2013; Wasala 2013). This raises the possibility that
some disease modifying approaches to treatment of DMD might
even increase the severity of cardiac dystrophinopathy - empha-
sising the need to include measurement of cardiac function in the
overall evaluation of patients.
Why it is important to do this review
Cardiomyopathy is now the most important limiting factor for
long-term survival in BMD and DMD patients. Furthermore,
improved management leading to a delay in loss of ambulation
could potentially stress an already vulnerable myocardium and
thus increase the risk of symptomatic cardiac involvement for this
group of patients in the future. The purpose of this review is
to systematically review the evidence for early intervention as a
means of preventing symptomatic cardiomyopathy, and the best
currently available treatments for established cardiac involvement
in the dystrophinopathies.
O B J E C T I V E S
To assess the effects of interventions for preventing or treating car-
diac involvement in DMD, BMD, and XLDCM, using measures
of change in cardiac function over six months.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included double- and single-blind randomised or quasi-ran-
domised trials and the first arm of cross-over controlled trials that
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compared the effects of an intervention versus another interven-
tion, placebo or standard treatment. We did not include longitu-
dinal, observational or open non-randomised studies in the Re-
sults section, but we considered them in the Discussion. (Quasi-
randomised trials use methods of allocation that are not truly ran-
dom, such as alternation, and allocation by date of birth or case
record number.)
Types of participants
All patients, including children and adults of all ages, confirmed
to have a dystrophinopathy (DMD, BMD or XLDCM). Diagno-
sis confirmed by muscle biopsy showing reduced or absent dys-
trophin staining and/or DNA studies showing a deletion, dupli-
cation, nonsense or missense mutation in the dystrophin gene.
Types of interventions
Pharmacological and non-pharmacological treatments known to
have an effect on improving or reversing the physiological effects
of dilated cardiomyopathy and pharmacological agents and cell
therapies that have an effect on skeletal muscle function (i.e. the
natural history of the disease). We planned to analyse data for each
type of intervention separately.
Types of outcome measures
Primary outcomes
Dystrophinopathies typically cause profound and progressive
physical disability, so even in the context of severe dilated car-
diomyopathy, patients usually experience few if any cardiac symp-
toms. Therefore it is rarely possible to differentiate death in the
context of a chest infection with associated respiratory failure from
death of primary cardiac aetiology. Indeed it is likely that the
occurrence of a lower respiratory infection in a patient with ad-
vanced cardiomyopathy can precipitate cardiorespiratory deaths.
For this reason we have chosen surrogate measures of cardiac func-
tion rather than morbidity and mortality as our primary outcome
measure.
We assessed changes in cardiac function following a six-month pe-
riod of intervention using ’equivalent techniques’ such as echocar-
diography (ejection fraction (EF), fractional shortening (FS),
ventricular dimensions: left ventricular systolic diameter (LVsd),
left ventricular diastolic diameter (LVdd), wall motion), tissue
Doppler echocardiography, cardiac magnetic resonance imaging
(CMRI), and gated radionuclide imaging (ejection fraction). For
each, we divided reported outcomes into those measuring ben-
efit (i.e. stable or improved) and those measuring deterioration.
In children, in whom echocardiography is usually the preferred
intervention, measuring FS and EF have been shown to correlate
well with other modalities such as CMRI (Soslow 2016; Spurney
2015).
Secondary outcomes
We planned to assess all secondary outcome measures as either
unchanged/improved or worse after a six-month intervention pe-
riod.
1. The size of metabolically abnormal areas of myocardium
identified with other forms of cardiac imaging: PET, SPECT and
31PMRS.
2. Improvements in quality of life measures, such as the
Paediatric Quality of Life Inventory (PedsQL) for children
(Varni 1999) and, for adults over 16 years of age, the
Individualized Neuromuscular Quality of Life Questionnaire
(INQol) or Short-Form 36-item Health Survey (SF-36) (Vincent
2007; Ware 2007).
3. The occurrence of one or more adverse events reported by
study investigators.
Search methods for identification of studies
Electronic searches
We searched the following databases on 16 October 2017.
• Cochrane Neuromuscular Specialised Register (Appendix
1).
• Cochrane Central Register of Controlled Trials
(CENTRAL, in the Cochrane Register of Studies; Appendix 2).
• MEDLINE (1996 to 16 October 2016; Appendix 3).
• Embase (1980 16 October 2016; Appendix 4).
We searched the following trials registries:
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (30 August 2018; Appendix 5)
• World Health Organization International Clinical Trials
Registry Platform (ICTRP; www.who.int/ictrp/en/) (31 July
2018; Appendix 6).
Searching other resources
We reviewed conference proceedings for non-published stud-
ies identified as published abstracts in our literature search and
screened bibliographies of identified manuscripts for studies not
identified by the search. We did not perform a separate search for
non-randomised studies but will refer in the Discussion to those
non-randomised studies identified during the search for RCTs.
Data collection and analysis
Selection of studies
All three review authors (RQ, JB, andTB) independently reviewed
the titles and abstracts identified from the searches. The authors
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obtained the full text of all potentially relevant studies for indepen-
dent assessment. All three authors independently decided which
trials met the inclusion criteria. There were no disagreements.
We selected only randomised and quasi-randomised controlled
trials, as well as cross-over trials, for inclusion. In the Discussion,
we reviewed open studies, longitudinal observational studies and
individual case reports but only discussed studies in which the
diagnosis, intervention, pre-treatment and post-treatment states
were adequately described and in whom follow-up for at least six
months was available.
The Cochrane Neuromuscular Managing Editor checked results
from clinical trials registry searches.
Data extraction and management
Two review authors (TB and RQ) independently extracted data
onto pre-agreed data extraction forms which the third author (JB)
then reviewed and approved. There were no disagreements. One
author (TB) entered data into the Cochrane statistical software,
Review Manager 5 (RevMan 5), and a second author (JB) or
a member of the Cochrane Neuromuscular Editorial team (RB)
checked data entry (RevMan 2014). We planned to contact trial
authors directly in case of any missing data. TheManaging Editor
entered data into Characteristics of studies awaiting classification
and Characteristics of ongoing studies tables.
Assessment of risk of bias in included studies
All three review authors independently assessed studies for risk of
bias using pre-agreed criteria, described in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011), and we
graded each trial as being at high, low or unclear risk of bias for the
following domains: sequence generation; allocation concealment;
blinding of participants and personnel; blinding of outcome asses-
sors; incomplete outcome data; selective outcome reporting; and
other sources of bias.
Measures of treatment effect
Had there been sufficient data, we would have calculated the
weighted treatment effect of identified trials using RevMan 2014
to combine risk ratios (RR) with 95% confidence intervals (CIs)
and risk differences (RDs) with 95% CIs for dichotomous out-
comes, and mean differences (MDs) and 95% CIs for continuous
outcomes.
Unit of analysis issues
Because of the progressive nature of dystrophinopathies, a poten-
tial source of bias might have occurred if the treatment arm pre-
ceded placebo in studies with cross-over designs. For this reason,
we planned to only analyse the first arm of any cross-over study.
Dealing with missing data
If necessary, we planned to attempt to contact trial authors for
missing data, including numbers of dropouts and deaths and
whether or not they performed an intention-to-treat analysis.
Assessment of heterogeneity
We planned to carefully evaluate all possible causes of heterogene-
ity and, where appropriate, to report the Chi² and I² statistics. We
would have considered Chi² values of P = 0.1 or less to indicate
significant heterogeneity.
Assessment of reporting biases
Weplanned to assess the potential effect of outcome reporting bias
by inspecting forest plots and preparing forest plots, if there were
sufficient RCTs.
Data synthesis
If we identified two or more studies comparing the same treat-
ments, we planned to use RevMan to pool their results, employing
methods appropriate to the type of outcome measures reported.
Dichotomous outcomes give proportions for each treatment group
and the treatments are usually compared using the ratio of the
proportions known as the risk ratio (RR). We planned to com-
bine studies to give an overall RR using fixed-effect analysis unless
there was significant evidence of heterogeneity between studies,
in which case a random-effects analysis would be more appropri-
ate. Counted episodes may be expressed as differences in rates/
unit time at risk with standard errors. In that event the simplest
analysis would have been to use the generalised inverse variance
(GIV) facility in RevMan to obtain and test the pooled difference
between treatment effects.
’Summary of findings’ tables
We created ’Summary of findings’ tables using GRADEpro soft-
ware (GRADEpro GDT 2015), and presented the following out-
comes:
• Change in cardiac function after six months;
• Size of metabolically abnormal areas of myocardium;
• Improvements in quality of life measures; and
• Adverse events.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness andpublicationbias) to
assess the certainty of a body of evidence (studies that contributed
data for the prespecified outcomes).We followedmethods and rec-
ommendations described in Chapters 11 and 12 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
RQ and JB assessed the certainty of evidence. They downgraded
the randomised controlled trial evidence from high to moderate,
low or very low certainty depending on the presence of the five
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GRADE factors. We downgraded once if any single consideration
was serious and twice if very serious. We documented decisions to
downgrade or upgrade the certainty of evidence using footnotes.
Subgroup analysis and investigation of heterogeneity
We planned to undertake subgroup analysis based on:
1. diagnosis (DMD, BMD and XLDCM); and
2. age (adult versus child less than 16 years of age).
Within each group we planned to use the I² statistic for hetero-
geneity and if its value had been greater than 50% we would have
scrutinised the trials and forest plots for differences to explain the
heterogeneity. If we found no explanation, wewould have repeated
the analysis using a random-effects model.
Sensitivity analysis
We planned to perform a sensitivity analysis to ensure robustness
of findings. This could include repeating the analysis but omit-
ting results from studies with cross-over design, smaller trials, or
commercially-led trials, and those lacking allocation concealment
or blinding.
R E S U L T S
Description of studies
Results of the search
We identified a total of 635 references from searches of the
Cochrane Neuromuscular Specialised Register, MEDLINE, Em-
base, and CENTRAL. After removing duplicate records, we were
left with 472 unique records. Following a review of the abstracts,
we obtained the full texts of 14 studies, of which only 5 were
ultimately suitable for inclusion (see Figure 1 for a flow chart il-
lustrating the study selection process). We described reasons for
excluding studies in the Characteristics of excluded studies tables.
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Figure 1. Study flow diagram illustrating the study selection process.
We reviewed and excluded nine other studies of pharmacological
agents for cardiomyopathy. Six did not have a randomised con-
trolled design (one was a follow-up study to one of the RCTs,
Duboc 2007, which provided additional outcome information for
the original study (Duboc 2005)). We reviewed reports of three
RCTs of novel disease-modifying agents, which included cardiac
evaluations as safety assessments.However, ultimately we excluded
them because of insufficient information on cardiac status before
and after the intervention.
Searches of ICTRP and ClinicalTrials.gov produced 43 and 69
records, respectively, of which we included 13 as Ongoing studies.
Three further registrations had published data and we added them
to Studies awaiting classification.
Included studies
See Characteristics of included studies.
Prophylactic use of perindopril versus placebo in DMD
Duboc 2005 reported a two-phase study conducted over five years,
comprising an initial 36-monthRCTphase (phase 1) and an open-
13Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated
cardiomyopathy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
label 24-month continuation phase (phase 2), to assess the effect
of prophylactic use of perindopril on the development and pro-
gression of left ventricular dysfunction in children with DMD.
Participants were recruited from 10 centres in France and had ge-
netically proven DMD, normal cardiac examination and LVEF of
more than 55% at baseline as measured by radionuclide ventricu-
lography. Entry criteria required participants to tolerate a 1 mg
test dose of perindopril, to have systolic blood pressure of at least
80 mmHg supine or more than 70 mmHg sitting, to be on no
other cardioactive drugs, with blood urea nitrogen of more than
7 mmol/L and no contraindications to ACE inhibitor therapy.
It was unclear from the initial publication whether participants
were taking steroid therapy concurrently or had cardiac devices
implanted (Duboc 2005). However, in their subsequent paper re-
porting long-term (10-year) follow-up (Duboc 2007), the trial au-
thors stated that no other pharmaceutical agent was being admin-
istered during the initial randomised phase of the study.
A total of 57 patients aged 9.5 to 13 years were recruited and
studied in phase 1 and randomly allocated to receive 2 mg to
4 mg perindopril once a day (active treatment: N = 28; mean
age 10.7 years (standard deviation (SD) 1.2); placebo group: N
= 29; mean age 10.6 years (SD 1.2)). Baseline characteristics of
both groups were similar. Outcome measures included detailed
serial clinical and drug tolerance evaluations and routine labo-
ratory blood testing. Resting radionuclide ventriculography was
performed at baseline, at 36 months planned study end (phase 1),
and at 60months (phases 1 and 2). Differences between treatment
and placebo groups were assessed using Chi² analysis (P < 0.05 for
significance). One participant did not complete phase I for reasons
unstated. However, as even this patient had LVEF% measured at
36 months, follow-up in phase I was complete. Mean LVEF at the
start of phase I was 65.0% (SD 5.4) in the 57 participants.
During phase 2, the open-label extension (Duboc 2005), three ad-
ditional patients withdrew from the study (initial active therapy, n
= 1) initial placebo therapy n = 2) for personal reasons, and none
had experienced adverse events during phase 1. Furthermore, beta-
blocking drugs were co-prescribed for supraventricular arrhyth-
mias in nine patients during phase 2 (initial active therapy, n = 4;
initial placebo therapy, n = 5). The trial authors do not address the
possible confounding effects of these cardioactive drugs but state
that none of those on beta-blockers had LVEF of less than 45% at
60 months.
Lisinopril versus losartan in established cardiomyopathy
Allen 2013 compared the benefits of lisinopril (an ACE inhibitor)
0.07mg/kg (5mg/day) with losartan (an ARB) 0.7mg/kg (25mg/
day) in a randomised, double-blind, controlled trial of 23 enrolled
(22 randomised) DMD patients, newly diagnosed with cardiac
dystrophinopathy. After one withdrawal, 12 participants were ran-
domised to lisinopril (median age 12.5 years, range 10 to 21) and
10 to losartan (median age 15.5 years, range 7 to 27 years). Car-
diomyopathy was defined on echocardiography by a fall in LVEF
of 10% from baseline and subsequently reassessed four-monthly
over 12 months. Median age in the lisinopril group was 12.5 years
(range 10 to 21 years) compared to 15.5 years (range 7 to 27 years)
in the losartan group. Siblings were randomised to the same treat-
ment arm. Initial doses were doubled if the LVEF decreased by 5%
to 10% and participants were withdrawn from further study if the
LVEF fell further by more than 10%. Concomitant therapy with
corticosteroids, beta-blockers or both were allowed. Although not
stated, the trial authors imply that participants were already taking
steroid therapy, but it is unclear whether beta-blockers could be
initiated during the study. Too few participants in the study were
taking beta-blockers (n = 0 in lisinopril group; n = 2 in the losar-
tan group) to allow separate analysis of the effects. Mean ejection
fractions were similar at baseline (LVEF lisinopril 47.5% versus
losartan 48.4%).
Idebenone versus placebo in subclinical cardiomyopathy
Buyse 2011 conducted a small (N=21) randomised, double-blind,
placebo-controlled study of idebenone, an antioxidant, in boys
aged 8 to 16 years old with DMD who had subclinical cardiomy-
opathy, defined by the presence of reduced radial strain measure-
ments in the postero-lateral segments of the left ventricular wall
on echocardiography. Thirteen boys received idebenone 150 mg,
and 8 received placebo. The mean age in the idebenone group was
10.8 years (SD 1.9) and in the placebo group 13.4 years (SD 2.1).
Exclusion criteria included concomitant use of ACE-inhibitors or
other antioxidants or the presence of an already established car-
diomyopathy (fractional shortening of less than 20% or LVEF of
less than 40%). The study was partly funded by Santhera Phar-
maceuticals, manufacturer of idebenone, and randomisation was
2:1 for idebenone taken three times per day or placebo. The pri-
mary outcome was change inmeasures of peak left ventricular pos-
tero-lateral radial strain between active and placebo treated groups
and change within each group from baseline over 12 months. A
range of other parameters were also measured, including cardiac
biomarkers (troponin-1 and pro-BNP) and respiratory and skele-
tal muscle strength.
Eplerenone versus placebo
In a multicentre, randomised, placebo-controlled trial, Raman
2014 compared the cardioprotective effect of adding eplerenone
(25 mg orally) or placebo to established treatment with an ACE
inhibitor or ARB for 12 months in 42 males with DMD. Twenty
participantswere treatedwith eplerenone and22with placebo, and
most participants were already receiving ACE inhibitors (18 in the
active eplerenone treatment group; 20 in the placebo group). The
median age in years (IQR) in the eplerenone group was 14.5 (12.0
to 18.5) and in the placebo group 15.0 (11.0 to 19.0). Eight partic-
ipants in the eplerenone group and nine in the placebo group were
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also taking beta-blockers, and two were taking regular furosemide.
Other concomitant non-cardiac medications included multivita-
mins, coenzyme Q10, vitamin D, calcium supplements, proton
pump inhibitors, and corticosteroids. Cardiomyopathy was as-
sessed using cardiac magnetic resonance imaging (MRI), which
included gadolinium-based contrast injection. Participants had to
have genetically proven DMD or a classical phenotype and be
older than 7 years.MRI had to show all of the following features at
study entry: myocardial systolic dysfunction, with one ormore left
ventricular segments showing late gadolinium enhancement but
with left ventricular ejection fraction of at least 45%. Exclusion
criteria were the presence of anMRI-incompatible implant, severe
claustrophobia, allergy to gadolinium contrast, previous treatment
with eplerenone or spironolactone, use of a potassium-sparing di-
uretic or other interventional agent within four weeks of the study
or five half-lives of the drug. Eplerenone was administered in a
dose of 25 mg on alternate days for the first month then daily
if the serum potassium (K+) concentration remained 5.5 mmol/
L or below. The primary outcome was change in left ventricular
circumferential strain from baseline to 12 months. Secondary out-
comes were change in left ventricular circumferential strain from
baseline to 6 months and changes in LVEF% and extent of late
gadolinium enhancement at 6 and 12 months. Investigators also
measured biomarkers: serum creatine kinase-MB (CK-MB), tro-
ponin-1 and osteopontin, and adverse events, including admission
to hospital for heart failure, cardiac arrhythmia, death and serum
K+ of more than 5.5 mmol/L.
Growth hormone versus placebo
One study assessed the effects of growth hormone (GH) therapy on
cardiac structure and function in patients with DMD and BMD.
Ten consecutive patients with BMD and six with DMD were
randomised to receive either recombinant GH (DMD: 0.23 mg/
kg/week; BMD: 0.07 mg/kg/week) or placebo for three months
(Cittadini 2003). The mean age of the participants was 13 years
(SD 2) in those with DMD, and 39 years (SD 3) in those with
BMD. The diagnosis was confirmed in all by dystrophin staining
of skeletal muscle biopsies. The BMD participants were receiving
background therapy including fosinopril 20 mg/day to 30 mg/day
(ACE inhibitor), warfarin, magnesium supplements, pidolatum,
antioxidants (vitaminsE,C, glutathione, ubiquinone), furosemide
and deflazacort. One participant in each group was also receiving
digoxin and amiodarone. All DMD participants were receiving
deflazacort, fosinopril and antioxidants (vitamin E, glutathione
and ubiquinone). Cardiac evaluation comprised ECG cardiomy-
opathic index (QT-PQ ratio, normal values being 2.2 to 4.6 s),
and 24-hour ECG monitoring and echocardiography (M-mode,
2D and echo-Doppler), measures of left ventricular size and func-
tion by a sonographer blinded to treatment allocations. Measures
of skeletal muscle function included timed function tests (timed
Gowers’ manoeuvre, time to climb four standard stairs, timed 10-
metre walk, and ’dynamic index’). Pulmonary function measures
comprised forced vital capacity (FVC), maximal voluntary venti-
lation, and maximal expiratory pressure.
Excluded studies
See Characteristics of excluded studies
We excluded five studies that did not have a randomised controlled
design (Folkers 1985; Ishikawa 1995; Kajimoto 2006;Matsumura
2010;Rhodes 2008), three safety studieswithout cardiac outcomes
(Mendell 2013; Voit 2014), and one long-term non-randomised
phase of an included study (Duboc 2007).
Studies awaiting classification
We listed three studies in the Studies awaiting classification section.
A trial of oral carvedilol versus ramipril stopped early; the ICTRP
record states that no results are available, but this requires con-
firmation (EUCTR2008-007236-18-IT). We matched two Clin-
icalTrials.gov records to trial reports (Leung 2014; Salehi 2017).
Salehi 2017 studied the effects of coenzymeQ10 in 25 randomised
participants, who were said to have genetically confirmed DMD,
but as the trial has female participants, we plan to contract the
trial authors to confirm eligibility. Leung 2014 was a randomised,
placebo-controlled trial of sildenafil in DMD, which was stopped
early for harm (worsening left ventricular end systolic volume on
cardiac MRI). We did not initially consider it for inclusion, but
as data are available from an interim analysis on 15 participants
who completed the six-month trial, we will re-assess its eligibility
when we update the review.
Ongoing studies
We added 13 trials from searches of clinicaltrials.gov or IC-
TRP to Characteristics of ongoing studies tables (FOR-DMD
2012; ISRCTN50395346; NCT00606775; NCT00819845;
NCT01126697; NCT01350154; NCT01648634;
NCT02354352; NCT02432885; NCT02485938;
NCT03340675; NCT03406780; NCT03439670).
Risk of bias in included studies
See Figure 2 for an illustration of the review authors’ ’Risk of bias’
assessments for all included studies across all domains.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The perindopril study did not provide sufficient details on how
participants were randomised (Duboc 2005). In Allen 2013, the
Nationwide Children’s Hospital investigational pharmacy per-
formed the randomisation. Siblings were randomised to the
same treatment arm, and we assessed the risk of bias from ran-
dom sequence generation as unclear. For the idebenone trial
(Buyse 2011), randomisation was computer generated by a third
party, Averion International, Switzerland. In the eplerenone study
(Raman 2014), study participants were randomised using com-
puter-generated blocks centrally, with only the study statistician
and investigational pharmacy aware of the randomisation assign-
ments. No details were provided as to how randomisation was per-
formed in the growth hormone study (Cittadini 2003).
Allocation concealment forDuboc 2005, Allen2013 andCittadini
2003 was unclear. A third party (Averion, Switzerland) performed
allocation concealment in the idebenone study (Buyse 2011). In
Raman 2014 there was good allocation concealment with only
the study statistician and institutional pharmacy knowing the ran-
domisation assignments.
Blinding
All five included studies were performed in a double-blind fashion.
Incomplete outcome data
We considered the following studies as being at low risk of bias
for incomplete outcome reporting: Duboc 2005, Buyse 2011 and
Raman 2014. Cittadini 2003 did not provide information about
compliance or report whether or not there were any dropouts. Six
of the 23 participants in Allen 2013 dropped out and we judged
the study at high risk of attrition bias.
Selective reporting
Raman 2014 did not provide data to substantiate findings, and
Cittadini 2003 presented left ventricular mass index, end-systolic
stress and ejection fraction results graphically. We did not identify
any other selective reporting.
Other potential sources of bias
The idebenone trial by Buyse 2011 was in part industry funded,
and we assessed the risk of other bias as high. In Cittadini 2003,
participants were taking other medications for cardiomyopathy;
we considered this to confer a high risk of bias. In Allen 2013 the
number of participants receiving corticosteroids was greater in the
lisinopril group, and in Raman 2014, although it is not possible to
determine whether concomitant therapy confounded the results,
we consider the risk high.
Effects of interventions
See:Summaryof findings for themain comparisonProphylactic
perindopril (2 mg to 4 mg daily) versus placebo in DMD;
Summary of findings 2 Lisinopril (0.7 mg/kg daily) versus
losartan (0.7 mg/kg daily) for established cardiomyopathy in
DMD; Summary of findings 3 Idebenone (3 daily tablets of
150 mg) versus placebo for subclinical cardiomyopathy in DMD;
Summary of findings 4 Eplerenone (25 mg daily) compared to
placebo for DMD; Summary of findings 5 Growth hormone
(0.23 mg/kg/week for DMD and 0.07 mg/kg/week in BMD SC
injection) versus placebo for DMD and BMD
Prophylactic perindopril versus placebo in DMD
One study compared prophylactic perindopril versus placebo in
DMD (Duboc 2005).
Primary outcome: change in cardiac function after six
months
Duboc 2005 did not provide data on numbers of participants
whose cardiac function improved or remained stable versus dete-
riorated, nor did authors report outcomes for the six-month time
period. The trial authors did report a dichotomous cardiac func-
tion outcome: the number of participants with an LVEF of less
than 45% at the end of each study phase (36 months and 60
months).
At the end of phase 1 (the randomised phase), LVEF remained
normal in most participants, and there was no significant differ-
ence in mean LVEF of either group (exact P value not given).
Baseline LVEF was 65.0% (SD 5.5) in the treated group (N = 28)
and 65.5% (SD 5.5) in the placebo group (N = 29). At the end of
36 months, mean LVEF was 60.7% (SD 7.6) in the treated group
versus 64.4% (SD 9.8) in group 2. The difference between groups
was not statistically significant (exact P value not given). How-
ever, one participant in each group had an LVEF of less than 45%
(i.e. established cardiomyopathy) at 36 months (RR 1.04, 95%
CI 0.07 to 15.77; very low-certainty evidence; N = 57; Analysis
1.1).
We downgraded the certainty of evidence three times, fromhigh to
very low, because of serious imprecision (small study size and low
event rate), study limitations, and indirectness (a three-year follow-
up is too short at this stage of DMD to detect effects on cardiac
function). See the Discussion for data from the non-randomised
phase 2 of the study and long-term follow-up (Duboc 2005;
Duboc 2007).
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Secondary outcomes
Size of metabolically abnormal areas of myocardium
Not reported.
Improvements in quality of life measures
Not reported.
Adverse events
After 36 months, 19/28 participants in the treatment group had
reported at least one adverse event, compared to 17/29 patients
in the placebo group (RR 1.16, 95% CI 0.78 to 1.72; N = 57;
low-certainty evidence). The events were similar in nature in each
group.
We downgraded the certainty of evidence fromhigh to lowbecause
of serious imprecision (small study size) and study limitations.
Lisinopril versus losartan for established
cardiomyopathy in DMD
One trial compared lisinopril versus losartan for established car-
diomyopathy in DMD (Allen 2013).
Primary outcome: change in cardiac function after six
months
In Allen 2013, the authors do not quote the numbers whose
LVEF% improved or stabilised versus those in whom it deterio-
rated, which we specified as our primary outcome; however, the
trialists reported the number whose LVEF fell below 45%. The
other primary trial outcome was reduction in mean LVEF, which
trialists reported after four months, eight months, and one year of
therapy.
MeanLVEFswere similar at baseline: 47.5% in the lisinopril group
(N = 12) and 48.3% in the losartan group (N = 10) (P = 0.93).
At eight months, mean LVEF% was similar in the two groups:
52.9% in the lisinopril group (N = 10) and 53.7% in the losartan
group (N = 9). Trialists did not report SDs.
LVEF improved in each group from baseline to 12 months (lisino-
pril group, P = 0.02 and losartan group, P = 0.03), but there was
no important difference in LVEF between the two groups among
participants who provided data at 12 months (lisinopril 54.6%
(SD 5.19) versus losartan 55.2% (SD 7.19); MD −0.60%, 95%
CI −6.67 to 5.47; 16 participants; very low-certainty evidence).
The study was curtailed early because of funding shortfalls, but
the trial authors showed clearly where data were missing.
We downgraded the certainty of evidence three times, from high
to very low, because of serious imprecision (small study size and
CI that included clinically important effects in either direction)
and study limitations (multiple but not controlled concomitant
medications, and a large number of dropouts in the lisinopril group
(due to cessation of funding (n = 5), allergic reaction (n = 1) and
poor LVEF at the start of the study or during the study (n = 3)).
Secondary outcomes
Size of metabolically abnormal areas of myocardium
Not reported.
Improvements in quality of life measures
Not reported.
Adverse events
The paper did not report findings from the standardised question-
naire used to collect adverse events. Two participants randomised
to the losartan group were removed from the study; one due to an
allergic reaction and another who exceeded the safety standard of
a greater than 10% decrease in ejection fraction.
We downgraded the certainty of evidence from high to very low
because of serious imprecision (small study size) and serious study
limitations (selective reporting).
Idebenone versus placebo for subclinical
cardiomyopathy in DMD
One trial compared idebenone versus placebo for subclinical car-
diomyopathy in DMD (Buyse 2011).
Primary outcome: change in cardiac function after six
months
Buyse 2011 reported outcomes at one year but not at six months.
The trial authors did not provide data for our primary outcome
(number of participants in whom left ventricular function im-
proved or stabilised versus deteriorated). They reported continu-
ous cardiac function outcomes comparing the difference between
idebenone treatment and placebo for global ventricular function
and left ventricular peak strain measures.
In terms of measures of global ventricular function, the mean
change in fractional shortening from baseline to 12 months was
1.4 (SD 4.1) in the idebenone group and 1.6% (SD 2.6) in the
placebo group (MD −0.20%, 95% CI −3.07 to 2.67; N = 21).
Corresponding changes in ejection fraction were−1.9% (SD 9.8)
in the idebenone group and 0.4% (SD 5.5) in the placebo group
(MD −2.30%, 95% CI −9.18 to 4.58; N = 19).
We downgraded the certainty of evidence three times for these
measures from high to very low because of very serious impreci-
sion (downgraded twice for imprecision because the trial was small
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and CI included clinically relevant effects in either direction), and
once for study limitations (baseline imbalance), and some indi-
rectness (participants appeared to be at a more advanced stage of
cardiomyopathy than ’pre-clinical’ but were not receiving ACE
inhibitors).
Posterolateral left ventricular peak strain measures were lower at
baseline in those randomised to idebenone. This was because those
randomised to idebenone (N = 13) were significantly older than
those randomised to placebo (N = 8). Idebenone showed an im-
provement in left ventricular peak systolic radial strain measures
from baseline compared to placebo. Themean increase was 17.3%
(SD 13.1) in the idebenone group versus 7.5% (SD12) P = 0.067)
in the placebo group (MD 9.80%, 95% CI −1.99 to 21.59;
Analysis 3.3; low-certainty evidence). The change in systolic radial
strain rate left ventricular inferolateral wall in the idebenone group
was 0.5 s−1 (SD 0.6; N = 10) and in the placebo group 0.0 s−1
(SD 0.9; N = 7) (MD 0.50 s−1, 95% CI −0.26 to 1.26; Analysis
3.4; very low-certainty evidence).
We downgraded the certainty of evidence from high to very low
because of serious imprecision (the trial was small and CI included
clinically relevant effects in either direction), study limitations
(baseline imbalance) and indirectness.
Due to the significant age-related baseline difference between the
groups, the authors performed a prespecified secondary analysis
to determine percentage change from baseline. This showed a
104.4% change from baseline for idebenone compared to 28.9%
for placebo (P = 0.030; SD for changes not given).
See Analysis 3.5; Analysis 3.6; Analysis 3.7; Analysis 3.8 for other
cardiac measures from this study.
Secondary outcomes
Size of metabolically abnormal areas of myocardium
Not assessed.
Improvements in quality of life measures
Not assessed.
Adverse events
Trialists noted 92 adverse events, all rated as mild or moderate,
which were equally distributed between the groups. None of these
resulted in drug discontinuations or dropouts from the trial. The
most frequently reported adverse events were gastrointestinal, in-
fections and headache. Two moderately serious adverse events
(both traumatic fractures) occurred, one in each group.
We downgraded the certainty of evidence to moderate because of
serious imprecision (small study size).
Other outcomes reported in the trial
The study also measured the effect on cardiac biomarkers. Pro-
BNP levels were higher at baseline for those taking idebenone, and
there was a non-significant decrease during treatment. Pro-BNP
levels rose from baseline in the placebo group during the study;
however, this was not statistically significant. Cardiac troponin I
remained within normal parameters in both groups.
Early respiratory involvement was assessed by measuring peak
expiratory flow and static mouth pressures; and restrictive pul-
monary changes were measured by spirometry. There was a signif-
icant difference in the improvement of peak expiratory flow (PEF)
and PEF% predicted (P = 0.039 and P = 0.042, respectively) for
idebenone compared to placebo, which tended to have a down-
ward trend. This was despite the older age of the idebenone group.
There were also no significant between-group differences in upper
limb strength.
However, the study is innovative in using highly sensitive measures
of early segmental cardiomyopathy as its primary outcome. The
study had a number of limitations - older participant age in the
idebenone cohort, small sample size, lack of correction in analysis
for repeatmeasures, and use of an idebenone dose not corrected for
body mass index. Furthermore, although authors described those
recruited as having only preclinical cardiomyopathy, some seemed
to be at a more advanced stage on the basis of a reduced ejection
fraction (LVEF less than 55%) and/or fractional shortening (FS
less than 25%). Such patients would normally be prescribed ACE
inhibitor therapy, but this was an exclusion criterion of the study.
Overall this was primarily a drug tolerability study, and further
therapeutic studies are warranted.
Eplerenone versus placebo for DMD
One trial compared eplerenone versus placebo for DMD (Raman
2014).
Primary outcome: change in cardiac function after six
months
Raman 2014 does not state the number of participants whose
left ventricular function improved or stabilised versus the number
who deteriorated. The study reported results as the difference in
changes in LVEF% and circumferential strain between patients
receiving eplerenone or placebo from baseline to 6 months, 6 to
12 months, and baseline to 12 months. The study randomised 42
participants and gave the total number of participants completing
baseline, 6-month and 12-month visits, together with total num-
bers of analysable examinations, but the number of participants
providing data for the outcomes at each time point is not clear.
There was no significant difference in themedian decline of LVEF
from baseline to six months between the eplerenone group (0%,
IQR −3.8 to 4.0) and the placebo group (1.0%, IQR −5.0 to
2.1) (P = 0.474). From 6 months to 12 months, the decline in
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LVEF was smaller in the eplerenone group (1.6, IQR−0.8 to 2.9)
than in the placebo group (−2.8, IQR−5.7 to−1.8) (P = 0.036).
This difference was also present in the change from baseline to
12 months, when the median decline of LVEF in the eplerenone
group was−1.8% (IQR−2.9 to 6.0) versus−3.7% (IQR−10.8
to 1.0) in the placebo group (P = 0.032).
There were no significant differences in mean decline in left
ventricular systolic circumferential strain magnitude between the
eplerenone group (0.84% (SD 2.68)) and the placebo group
(0.38% (SD2.56)) from baseline to six months (P = 0.602 or from
6 months to 12 months (P = 0.379). At 12 months, the median
decline in left ventricular systolic circumferential strain was less in
the eplerenone-treated group (1.0%, IQR 0.3 to −2.2) than in
the placebo group (2.2%, IQR 1.3 to −3.1) (P = 0.020).
The trial authors considered an absolute difference of 1% in strain
units at 12 months as clinically significant.
We downgraded the evidence to very low certainty for study lim-
itations (the study did not control for concomitant medications,
which were numerous) and twice for imprecision; as the study was
small (N = 42 randomised), and measures of variance allow for the
possibility of a clinically important difference in either direction.
There was also some indirectness. LVEF% in some participants
would constitute ’definite cardiomyopathy’.
Secondary outcomes
Size of metabolically abnormal areas of myocardium
The extent of abnormal myocardium, as assessed by extent of late
gadolinium enhancement, was reduced over the first six months
of the trial by eplerenone therapy (mean change −2% (SD 6)
compared to placebo (mean change 4% (SD 6) (MD −6.00%,
95% CI−9.77 to−2.23; low-certainty evidence)) but not from 6
to 12months (MD4.00%, 95%CI 0.23 to 7.77) or from baseline
to 12 months (median change in the eplerenone-treated group
−1% (IQR −6 to 3 and in the placebo group −3% (IQR −5 to
4); P > 0.999; low-certainty evidence).
We downgraded the certainty of evidence twice, from high to low:
once for study limitations and once for indirectness. LVEF% in
some participants would constitute ’definite cardiomyopathy’; the
criteria for starting ACE inhibitor and beta-blocking therapy in
any of the participants was not stated (yet eplerenone was added
to this combination).
Improvements in quality of life measures
Not assessed.
Adverse events
In the placebo group, one participant withdrew at three months
due to digestive issues and a month after enrolment, one partic-
ipant died following a fat embolus. Authors did not report any
other significant adverse events. Trial authors describe other ad-
verse events asmild. In the placebo group, one participant reported
facial flushing after the first two doses and another experienced a
panic attack upon commencing the active treatment. We calcu-
lated the RR for serious adverse events as RR 0.37, 95% CI 0.02
to 8.48 (very low-certainty evidence).
We downgraded the certainty of evidence three times, to very low:
once for imprecision, as the trial was small (N = 39), once for study
limitations, and once for indirectness as the criteria for starting
ACE inhibitor and beta-blocking therapy in any of the participants
was not stated (yet eplerenone was added to this combination).
Other outcomes reported in the trial
There were no significant changes in the cardiac biomarkers tro-
ponin I, total creatine kinase and creatine kinase MB fraction dur-
ing the study period.
We have contacted the authors for missing data and are waiting
for a response.
Growth hormone versus placebo for DMD and BMD
One trial compared growth hormone (GH) versus placebo for
DMD and BMD (Cittadini 2003).
Primary outcome: change in cardiac function after six
months
Cittadini 2003 did not provide data on the numbers of partici-
pants whose heart function improved or stabilised versus deterio-
rated, and authors reported outcomes only at three - not at six -
months. The study authors reported continuous cardiac function
outcomes comparing LVEF and left ventricular mass index in par-
ticipants receiving GH or placebo for a three-month time period.
There were no between-group comparisons of echocardiographic
indices for the DMD group (N = 6) due to the small sample size;
left ventricular mass index, end-systolic stress and ejection frac-
tion results were presented graphically. Authors reported results
in BMD and DMD participants for active versus placebo therapy
separately.
We considered the certainty of evidence very low because of study
limitations, imprecision (N = 16), and indirectness (three-month
study duration rather than our specified six months).
In participants with BMD (N = 10), left ventricular volumes were
larger and LVEF lower compared with DMD participants. In the
GH-treated BMD participants, left ventricular mass increased by
approximately 42 g (trend towards increased left ventricular pos-
terior and anterior wall thickness) compared with a slight decrease
in these measurements in the placebo group. The authors reported
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a “concentric remodelling of the left ventricular cavity with a sig-
nificant increase of the relative wall thickness of 12%” in the GH-
treatedBMDgroup, compared tono change in the placebo-treated
group (no measures of variance reported). End diastolic volumes
did not change significantly over time.
In GH-treated DMDparticipants, the study authors report a 29%
increase in left ventricular mass compared to the placebo-treated
group. The study authors also report a non-significant trend for
increase in left ventricular fractional shortening (LVFS) in GH-
treated DMD participants.
Secondary outcomes
Size of metabolically abnormal areas of myocardium
Not assessed.
Improvements in quality of life measures
Not assessed.
Adverse events
Trial authors reported “no clinical relevant side effect”. There were
no observed cardiac arrhythmias or haematological adverse effects.
The certainty of this evidence was very low. We downgraded the
certainty of evidence three times: twice for study limitations and
once for imprecision. Additionally, the trial duration was only
three months.
Other outcomes reported in the trial
Authors observed no significant variations in the cardiomyopathic
index (which was abnormal at baseline in five BMD and three
DMD participants) during the study period.
Treatment and control groups were similar for blood biomarkers
at baseline. Seven of the 16 participants showed impairment of
GH/IGF1 axis and low circulating IGF1 levels. Plasma IGF-1 in-
creased by 82% in participants treated with GH but decreased by
9% in those receiving placebo. Thyroid function did not change
in either group. Plasma levels of BNP were elevated in all partici-
pants compared to controls but decreased by 40% in the treatment
group. There were no significant differences in timed function
tests or FVC.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Lisinopril (0.7 mg/kg daily) versus losartan (0.7mg/kg daily) for established cardiomyopathy in DMD
Patient or population: pat ients with established cardiomyopathy in DMD
Setting: 5 part icipat ing centres
Intervention: lisinopril (0.7 mg/ kg daily)
Comparison: losartan (0.7 mg/ kg daily)
Outcomes Anticipated absolute effects* (95% CI) Number of participants
(studies)
Certainty of the evidence
(GRADE)
Risk with losartan (0.7 mg/kg
daily)
Risk with lisinopril (0.7 mg/kg
daily)
Cardiac funct ion: assessed with
echocardiography; EF measured
by biplane Simpson’s rule f rom
the apical 4 chamber view
Follow-up: 12 months (f inal val-
ues)
The mean EF was 55.2% MD 0.60% lower
(6.67 lower to 5.47 higher)
16
(1 RCT)
⊕©©©
Very lowa
Size of metabolically abnormal ar-
eas of myocardium
Not reported
Improvements in quality of lif e
measures
Not reported
Adverse events
Follow-up: 12 months
Adverse events are not fully described. There were 2 withdrawals
because of adverse events, both in the losartan group (hives and
greater than 10% decline in eject ion f ract ion)
22
(1 RCT)
⊕⊕©©
Very lowb
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; DMD: Duchenne muscular dystrophy; EF: eject ion f ract ion; RCT : randomised controlled trial; RR: risk rat io.
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GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aWe downgraded the quality of evidence three t imes: twice for serious imprecision (small study size and CI that included
the possibility of clinically important ef fects in either direct ion) and once for study lim itat ions (mult iple but not controlled
concomitant medicat ions, and a large number of dropouts in the lisinopril group).
bWe downgraded the quality of evidence three t imes: once for imprecision (small study size) and twice for study lim itat ions
(the report does not provide results f rom the adverse event quest ionnaire described in the protocol and methods; and because
part icipants received mult iple concomitant medicat ions).
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Idebenone (3 daily tablets of 150 mg) versus placebo for subclinical cardiomyopathy in DMD
Patient or population: boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
Setting: Leuven, Belgium
Intervention: idebenone (3 daily tablets of 150 mg)
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Number of participants
(studies)
Certainty of the evidence
(GRADE)
Comments
Risk with placebo Risk with idebenone (3
daily tablets of 150 mg)
Change in cardiac funct ion
(change in f ract ional short-
ening)
assessed with: echocardio-
graphy
Follow-up: 12 months
The mean cardiac funct ion
(change in f ract ional short-
ening) was 1.6%
MD 0.20% lower
(3.07 lower to 2.67 higher)
21
(1 RCT)
⊕⊕©©
Very lowa,b
Non- signif icant
Change in cardiac funct ion
(change in eject ion f ract ion)
assessed with: echocardio-
graphy
Follow-up: 12 months
The mean cardiac funct ion
(change in eject ion f ract ion)
was 0.4%
MD 2.3% lower
(9.18 lower to 4.58 higher)
21
(1 RCT)
⊕⊕©©
Very lowa,b
Non- signif icant
Change in cardiac funct ion
(change in peak systolic ra-
dial strain in LV lateral wall
segments)
The mean cardiac funct ion
(change in peak systolic ra-
dial strain in LV lateral wall
segments) was 7.5%
MD 9.8% higher
(1.99 lower to 21.59 higher)
18
(1 RCT)
⊕⊕©©
Very lowa,b
Non- signif icant
Change in cardiac funct ion
(change in systolic radial
strain rate LV inferolateral
wall)
assessed with: per second
The mean cardiac funct ion
(change in systolic radial
strain rate LV inferolateral
wall) was 0 per second
MD 0.5 per second higher
(0.26 lower to 1.26 higher)
18
(1 RCT)
⊕⊕©©
Very lowa,b
Non- signif icant
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Size of metabolically abnor-
mal areas of myocardium
Not reported
Improvements in quality of
lif e measures
Not reported
Adverse events
Follow-up: 12 months
92 adverse events were reported, all rated as mild or
moderate, which were equally distributed between the
groups. None of these required drug discont inuat ions or
caused part icipants to drop out f rom the trial
21
(1 RCT)
⊕⊕©©
Lowa
-
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; DMD: Duchenne muscular dystrophy; LV: lef t ventricular; MD: mean dif ference; RCT : randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded for very serious imprecision (small study size and CI include clinically relevant ef fects in either direct ion) and
for baseline imbalance (older age in the idebenone group).
bThere was also some indirectness as some part icipants appears to be at a more advanced stage of cardiomyopathy than
’pre-clinical’, with a reduced eject ion f ract ion or f ract ional shortening, or both. Normally such pat ients would receive ACE
inhibitor therapy but this was an exclusion criterion in the trial.
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Eplerenone (25 mg daily) compared to placebo for DMD
Patient or population: boys with DMD and lef t ventricular eject ion f ract ion 45% or more
Setting: 3 centres in the USA
Intervention: eplerenone (25 mg daily)
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evidence
(GRADE)
Risk with placebo Risk with eplerenone (25
mg daily)
Change in cardiac func-
t ion: change (decline) f rom
baseline in lef t ventricular
strain assessed with: car-
diac magnetic resonance
imaging
Follow-up: 12 months
At 12 months, the median decline in lef t ventricular
systolic circumferent ial strain was less in the eplerenone-
treated group (1.0%, IQR 0.3 to −2.2) than in the placebo
group (2.2%, IQR 1.3 to −3.1) (P = 0.020)
- 42 randomised
(1 RCT)
⊕©©©
Very lowa
Change in cardiac func-
t ion: change in LVEF (base-
line to 6 months) assessed
with: cardiac magnetic res-
onance imaging
Follow-up: 12 months
The median decline of LVEF in the eplerenone group was
−1.8% (IQR −2.9 to 6.0) versus −3.7% (IQR −10.8 to 1.
0) in the placebo group (P = 0.032)
- 42 randomised
(1 RCT)
⊕©©©
Very lowa
Size of metabolically abnor-
mal areas of myocardium
(baseline to 12 months)
The median change in the eplerenone-treated group was
−1% (IQR −6 to 3) and in the placebo group −3% (IQR
−5 to 4), P > 0.999
- 42 randomised
(1 RCT)
⊕⊕©©
Lowb
Improvements in quality of
lif e measures
Not reported
Adverse events
Follow-up: 12 months
Study populat ion RR 0.37
(0.02 to 8.48)
42
(1 RCT)
⊕©©©
Very lowa26
In
te
rv
e
n
tio
n
s
fo
r
p
re
v
e
n
tin
g
a
n
d
tre
a
tin
g
c
a
rd
ia
c
c
o
m
p
lic
a
tio
n
s
in
D
u
c
h
e
n
n
e
a
n
d
B
e
c
k
e
r
m
u
sc
u
la
r
d
y
stro
p
h
y
a
n
d
X
-lin
k
e
d
d
ila
te
d
c
a
rd
io
m
y
o
p
a
th
y
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
45 per 1000 17 per 1000
(1 to 385)
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; DMD: Duchenne muscular dystrophy; IQR: interquart ile range; RCT : randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded three t imes: once for study lim itat ions (study did not control for concomitant medicat ions, which were
numerous) and twice for imprecision; the CI allows for the possibility of a dif f erence in either direct ion. Addit ionally LVEF%
in some part icipants would const itute ’def inite cardiomyopathy’; however, the criteria for start ing ACE inhibitor and beta-
blocking therapy in any of the pat ients is not stated (yet eplerenone was added to this combinat ion).
bDowngraded once for study lim itat ions (study did not control for concomitant medicat ions, which were numerous) and
imprecision (N = 39). Addit ionally, LVEF% in some part icipants would const itute ’def inite cardiomyopathy’; however, the
criteria for start ing ACE inhibitor and beta-blocking therapy in any of the pat ients is not stated (yet eplerenone was added to
this combinat ion).
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Growth hormone (0.23 mg/kg/week for DMD and 0.07/ kg/week in BMD SC injection) versus placebo for DMD and BMD
Patient or population: people with DMD or BMD (ages not stated)
Setting: Cardiomyology and Myology Centre of Naples Second University
Intervention: growth hormone (0.23 mg/ kg/ week for DMD and 0.07 mg/ kg/ week in BMD subcutaneous inject ion)
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Number of participants
(studies)
Certainty of the evidence
(GRADE)
Risk with placebo Risk with growth hormone
Change in cardiac funct ion: ejec-
t ion f ract ion
assessed with: echocardiography
Follow-up: 3 months
Outcomes were reported at 3 months. No between-group
comparisons of echocardiographic indices for the DMD group
(N = 6) were performed due to the small sample size; LV mass
index, end-systolic stress and eject ion f ract ion results were
presented graphically
The study authors report a non-signif icant trend for increase
in LV f ract ional shortening in growth-hormone-treated DMD
part icipants
16
(1 RCT)
⊕©©©
Very lowa,b,c
Size of metabolically abnormal ar-
eas of myocardium
Not reported
Improvements in quality of lif e
measures
Not reported
Adverse events None reported 16
(1 RCT)
⊕©©©
Very lowa,b,c
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
BMD: Becker muscular dystrophy; CI: conf idence interval; DMD: Duchenne muscular dystrophy; LV: lef t ventricular; RCT : randomised controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.28
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Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded twice for study lim itat ions: inadequate randomisat ion, confounding f rom concomitant medicat ions, and
select ive report ing (numerical results not provided).
bDowngraded for imprecision (N = 16).
cDowngraded once for indirectness: trial durat ion 3 months rather than the 6 months specif ied for this review.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
This systematic review identified five double-blind RCTs meeting
Cochrane criteria for inclusion (Allen 2013; Buyse 2011; Cittadini
2003; Duboc 2005; Raman 2014). The trials involved a total of
205 participants, and each trial assessed a different intervention.
No meta-analysis was possible because none of the interventions
were sufficiently similar for data to be combined.
Two studies, one of GH and one of idebenone, showed no mean-
ingful change in left ventricular function.
A study comparing idebenone with placebo in 21 boys with DMD
showed no difference in cardiac function between the two groups
after 12 months’ treatment. Reported adverse events were similar
between the treatment and placebo groups. We rated the certainty
of evidence from this study as very low.
The study comparing lisinopril with losartan, which was a short
duration study in a small patient cohort, suggested that ACE in-
hibitors andARBdrugswere equally beneficial in treating the early
stages of cardiac dystrophinopathy.
Long-term follow-up of perindopril treatment in boys with BMD/
DMD found only small changes in cardiac function over long
periods of time inmost boys, and there were few events, suggesting
a need for long-term studies with more participants.
In boys with DMD and early cardiac involvement who have al-
ready been established on ACE inhibitors or ARB drugs, treat-
ment with eplerenone reduced the decline both in measures of
left ventricular strain and LVEF% compared with placebo over 12
months.
The results of these studies provide low- or very low-certainty ev-
idence that it may be possible to modify the course of cardiomy-
opathy in patients with DMD and BMD with early use of ACE
inhibitors (Allen 2013; Duboc 2007), ARBs (Allen 2013), and
eplerenone (Raman 2014).
Data from open-label extension studies in a large cohort of DMD
patients suggest that corticosteroid treatment - used primarily for
muscle strengthening - delays the onset of and slows the course of
cardiomyopathy inDMD (Barber 2013; Schram 2013; Silversides
2003). Ongoing trials of newer disease-modifying agents need to
include heart assessments as a key outcome measures.
Evidence from non-randomised studies
Duboc 2005 reported a two-phase double-blind, randomised first
phase comparing perindopril 2 mg to 4 mg daily (group 1) and
placebo (group 2), lasting three years, followed by a two-year open-
label second phase at the same dose of perindopril. Duboc 2007
was a follow-up report after 10 years of treatment.
At the conclusion of phase 2 of this study at 60 months, both
groups showed significant decrease in LVEF: from65.0% (SD5.5)
to 58.6% (SD8.1) (P = 0.001) in those randomised to active treat-
ment in phase 1; and from 65.4% (SD 5.5) to 56.0% (SD 15.5)
(P = 0.006) in those initially randomised to placebo therapy in
phase 1. However, the authors stated that there was no statistically
significant difference in mean LVEF between the groups (58.6%
(SD 8.1) versus 56.0% (SD 15.5)) at 60 months.
Furthermore, only one participant treated with perindopril in
phase 1, compared to eight participants treated with placebo in
phase 1, had an LVEF of less than 45% (Chi² 5.699, P = 0.02).
The mean age of patients with or without depressed LVEF at
60 months was similar, and the benefits of 2 mg versus 4 mg of
perindopril were similar. The trialists go on to highlight that three
of eight participants from the initial placebo group with LVEF of
less than 45%died of congestive heart failure in the year after phase
2 completion, while the one participant from the group initially
allocated to perindopril with LVEF of less than 45% remained
alive.
The study showed little or no difference between perindopril and
placebo groups after three years and, even after 5 years (phases
1 and 2), the mean differences in measures of cardiac function
between the groups were not clinically significant. However, more
participants from the placebo arm of the RCT had LVEF of less
than 45% than in the treatment arm at the end of the open label
study, suggesting that a longer time interval may be required to
detect changes at follow-up.
A later publication, reporting 10-year follow-up from the original
study reported improved survival in the participants in the initial
perindopril-treated arm compared to the initial placebo-treated
arm (26/28 versus 19/29 alive at 10 years; Kaplan-Meier cumu-
lative survival P = 0.125 and log-rank Fisher exact test P = 0.02)
(Duboc 2007). However, authors did not state the precise mech-
anism of death, and some participants had also been treated with
beta-blockers (four perindopril-treated participants; five placebo-
treated participants in phase 1). The study has a number of other
weaknesses in that, although it showed that death occurred more
often in participants with reduced heart function, it was not pow-
ered to assess mortality and, although both active and placebo
groups were similar in age, the groups were not standardised by
disease severity.
One non-randomised study comparedACE inhibitors versus ACE
inhibitors plus beta-blockers in patients with DMD-related car-
diomyopathy. Participants were monitored with echo-measures of
LVEF% every 3 to 4 months over 12 months. Prior to ACE in-
hibitor treatment, 22 participants showed declining LVEF% over
time. ACE inhibitor therapy was started and doses modified if
further falls in LVEF% were observed. Beta-blockers were added
(N = 24) if resting heart rate on 24-hour ECG exceeded 100
beats per minute. LVEF% improved compared to baseline in both
groups (ACE inhibitors and ACE inhibitors plus beta-blockers)
(P < 0.001). However, the difference between groups was not sig-
nificant (Viollet 2012). More recently a number of novel disease-
modifying pharmaceutical agents (ataluren, eteplirsen, and dris-
30Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated
cardiomyopathy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
apersen) have been tested with regard to their effects on skeletal
muscle in phase II clinical trials. However, their effects on cardiac
function have yet to be reported (Bushby 2014; Mendell 2013,
Voit 2014). A meta-analysis of corticosteroids as a disease-modi-
fying treatment for DMD showed benefit over six months based
upon functional scores, but these trials did not include cardiac out-
come measures (Matthews 2016). However, data from long-term
prospective extension studies suggest that corticosteroids do pro-
vide some measure of cardiac protection (Burnett 2017; Schram
2013; Silversides 2003). Unfortunately, because corticosteroids are
now considered the ’gold standard of care’ for patients withDMD,
it would no longer be ethical to conduct RCTs to further exam-
ine their effects specifically on cardiac function in DMD. One
small prospective study assessed cardiac function at baseline and
after three months of corticosteroid therapy (prednisolone 5 mg/
kg/day on two consecutive days each week) in 25 patients with
either BMD, DMD or who were manifesting carriers of DMD
(Hussain 2014). LVFS was assessed by echocardiography at base-
line and after three months of treatment. LVFS% improved (P =
0.009) and left ventricular mass increased (P = 0.012) in those
on prednisolone treatment. Another large, prospective follow-up
study assessed cardiac function by echocardiography in 462 of 797
DMD patients frommultiple centres in the USA (MD STARnet),
291 of whom had received corticosteroids and 171 who had never
received corticosteroid treatment (Barber 2013). Cardiomyopa-
thy was defined as a fractional shortening of less than 28% or, if
fractional shortening measurement was not available, an ejection
fraction of less than 55%. Among those who had received corti-
costeroids, the mean treatment starting age was 7.4 years and the
mean treatment duration was 4.1 years. Cardiomyopathy devel-
oped in 202 of the 291 corticosteroid-treated boys, at a mean age
of 15.2 (SD 3.4) years, compared to all 171 of those who were
untreated, at a mean age of 13.1 (SD 4.8) years. A Kaplan-Meier
curve showed that corticosteroid therapy significantly delayed the
cardiomyopathy (P = 0.02, Chi² = 5.27). Furthermore, regression
analysis suggested that for every year of corticosteroid treatment,
cardiomyopathy was delayed by 4%. Survival was greatest in the
group who received carvedilol.
In a non-randomised study of carvedilol (Matsumara 2010), 41
DMDpatients received carvedilol, and 13 did not. All participants
were treated with an ACE inhibitor if the ejection fraction was
below 50% and were followed up every six months for five years.
Symptomatic heart failure occurred in more patients who had
not received carvedilol, and more participants in this group died
compared with those treated with carvedilol.
A retrospective review of ivabradine treatment in 13 DMD pa-
tients with dilated cardiomyopathy (defined as ejection fraction
less than 45%) compared with seven untreated patients demon-
strated improvement in left ventricular function in the ivabradine-
treated patients (Adorisio 2017).
There have been no RCTs of cardiac transplantation in patients
with inherited forms of muscle disease. However, in a retrospective
review of 29 transplant centres in the USA covering the period
1990 to 2005 (Wu 2010), outcomes after transplantation were
compared between 29 patients withmuscular dystrophy (52%had
BMD) and 275 age- and sex- matched ’controls’ who underwent
transplantation for non-ischaemic cardiomyopathy without mus-
cle conditions. One-year survival was 89% and 91% in the mus-
cular dystrophy and the non-muscle-affected group, respectively
(P > 0.5) and five-year survival was 83% and 78% (P = 0.5) for
muscular dystrophy and non-muscle-affected groups. This sug-
gests that a diagnosis of muscular dystrophy should not exclude
selected patients from being considered for cardiac transplanta-
tion.
At the time of writing this systematic review, several trials are
ongoing (see Characteristics of ongoing studies). These include
a trial of coenzyme Q10 and lisinopril (NCT01126697), and a
randomised, placebo-controlled trial of ACE inhibitors plus beta-
blockers to prevent the onset or change the course of cardiomyopa-
thy in DMD (ISRCTN50395346). Another ongoing trial is com-
paring daily corticosteroids (prednisolone or deflazacort) with in-
termittent prednisolone (10 days on and 10 days off ) (FOR-DMD
2012). The results of these studies are expected, and we plan to
include them in the next update of this review.
Overall completeness and applicability of
evidence
Currently data are limited to only small studies of a limited range
of interventions, but results from larger, ongoing trials are likely to
report and add to these data over the next few years. In future up-
dates we will consider including serum biomarkers as a secondary
outcome and longer-term outcome measures.
We found no studies for XLDCM.
Quality of the evidence
The certainty provided by the evidence to date is low or very low
due to the paucity of trials and the small numbers of participants
studied. Interventions were heterogeneous - none of the interven-
tions were investigated in more than one trial. In addition, data
were missing for the eplerenone study, which made further anal-
ysis of the results impossible. Most studies had some risk of bias
that lowers confidence in our estimates of effect, in some cases
substantially. Reporting was not always complete. Several trials did
not stratify for age or concomitant medications.
Potential biases in the review process
Studies of disease-modifying drugs such as eteplirsen (Mendell
2013), which have used cardiac function as a safety measure but
have not reported results, could be a potential source of bias for
this review as there may be meaningful data not available to the
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review authors. It is also possible that selective reporting in the
literature of only trials with positive results could have potentially
biased our review results. Furthermore, the studies that we have
reported were of short duration; longer duration non-randomised
studies might potentially show different results.
Agreements and disagreements with other
studies or reviews
We did not find data from other studies to support or refute the
data presented in this review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on the available evidence from RCTs, early treatment with
ACE inhibitors or ARBs may be comparably beneficial for peo-
ple with a dystrophinopathy; however, the certainty of evidence is
very low. Findings from non-randomised studies, some of which
have been long term, have led to the use of these drugs in daily
clinical practice. Very low-certainty evidence indicates that adding
eplerenonemight give additional benefit when early cardiomyopa-
thy is detected. No clinically meaningful effect for growth hor-
mone or idebenone was seen, although the certainty of the evi-
dence was also very low.
Implications for research
Opportunities to assess the effects of corticosteroids on cardiac in-
volvement in Duchenne muscular dystrophy (DMD) were missed
in early randomised controlled trials (RCTs). The opportunity to
perform further RCTs to examine the cardiac effects of corticos-
teroid therapy further has now been lost, as it would be unethical.
It is also increasingly difficult to justify placebo-controlled trials of
prophylactic use of ACE inhibitors or ARB therapy in DMD, so
we hope that the ongoing studywill provide the definitive evidence
to guide cardiacmanagementwhen it reports in 2018. Phase II and
phase III trials of novel, disease-modifying pharmaceutical agents
are ongoing. Assessing the effects of these agents on cardiac func-
tion from the outset might reduce the need for additional studies
specifically to assess cardiac effects later. Future studies could focus
on anti-arrhythmic and heart rate slowing therapies as a potential
strategy for preventing further decline in heart function; for ex-
ample, studies could compare the effect of these agents with beta-
blockers.
A number of pharmacological agents appear to be cardioprotective
in DMD and BMD, although the data from RCTs is limited to
results from studies of small participant numbers.The plethora of
potentially beneficial disease-modifying therapies and other med-
ications becoming available in the same timeframe on the basis of
’proof of concept’ results will make it challenging to recruit suffi-
cient participants from a relatively small pool of eligible patients.
Furthermore, even when an individual therapy or medication is
shown to be beneficial, there will still be a need to understand how
best to combine treatments to optimise patient outcomes without
adverse effects or increasing the overall burden of therapy for pa-
tients.
We graded the evidence reported as low or very low certainty
based upon the studies’ short duration, small numbers of par-
ticipants and missing data. DMD is a rare disorder, and finding
sufficient numbers of patients to power a study is not possible
without multicentre, multinational collaboration; thus adequately
powered RCTs in patients in this population are very expensive,
and the costs rise steeply with study duration. In an effort to con-
tain cost and secure funding, therefore, study designs have had
to become shorter and use more sensitive surrogate outcomes -
as exemplified well by the design and conduct of the eplerenone
study (Raman 2014). However, shorter study designs in fewer par-
ticipants may be insufficient to provide robust clinical evidence to
study cardiac involvement in DMD - with its wide inter-patient
variability in which the success of various interventions are prob-
ably time dependent. It seems unlikely, however, that the RCTs
ideally needed to arrive at the optimum cardiac management in
DMD are all affordable. To derive the most from what limited
number of studies can be funded, therefore, it is crucial that each
addresses an important clinical uncertainty and that the results
build on and not duplicate what is already accepted. It is only
in this way that cardiac management of patients with DMD can
move from theory to evidence-based care.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Allen 2013
Methods Randomised, parallel group, double-blind, multicentre study
Participants 23 boys with newly diagnosed DMD cardiomyopathy of any age
Median age (range) in years: lisinopril 12.5 (10 to 21); losartan 15.5 (7 to 27)
Concomitant corticosteroids, beta-blockers, or both, were allowed
Inclusion criteria:
Clinical course consistent with DMD, proven mutation of DMD gene or muscle dys-
trophin levels < 5% on muscle biopsy, Doppler echocardiogram with ejection fraction <
55%, ability to co-operate with testing
Lisinopril ≤ 5 mg, losartan ≤ 25 mg, or enalapril ≤ 5 mg treatment allowed provided
2 weeks washout and LVEF parameters acceptable (see exclusion criteria)
Exclusion criteria:
Current lisinopril≤ 5mg, losartan≤ 25mg, or enalapril≤ 5mg treatment (no washout)
Ejection fraction ≥ 55% or ≤ 40% after at least 2 weeks’ washout, of above drugs
Skeletal deformities or pulmonary anatomical variants that precluded consistent echocar-
diography measurements
Interventions ACE inhibitor (lisinopril) 0.07 mg/kg (5 mg/day) (N = 12)
ARB (losartan) 0.7 mg/kg (25 mg/day) (N = 10)
Outcomes Echocardiography at baseline and at 3 subsequent visits at 4-monthly intervals (4months,
8 months, 12 months)
Funding sources Duchenne muscular dystrophy Clinical Research Network grant from the Muscular
Dystrophy Association USA
Declarations of interest No competing interests
Notes ClinicalTrials.gov NCT01982695
Location: 5 sites in US
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation performed by the Nation-
wide Children’s Hospital investigational
drug pharmacy. Siblings were randomised
to the same treatment arm
Allocation concealment (selection bias) Unclear risk Not described
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Allen 2013 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The capsules of ACE inhibitor and ARB
were identical and the participants were not
informedof the treatment theywere taking.
Siblings were randomised to the same treat-
ment arm to reduce the risk of unblinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study assessors blinded until the termina-
tion of the study
Incomplete outcome data (attrition bias)
All outcomes
High risk Of 23 participants enrolled, 1 (losartan
group) immediately withdrew, 2were with-
drawn due to low ejection fraction and ur-
ticaria, respectively, 3 had only 3 echocar-
diographs performed due to termination of
funding
Selective reporting (reporting bias) Low risk No evidence of selective reporting for effi-
cacy outcomes. Methods for recording ad-
verse events described but no details re-
ported (other than withdrawals resulting
from adverse events)
Other bias High risk None identified
Concomitant medication: 0 in the lisino-
pril group and 2 in the losartan group re-
ceiving beta-blockers; 8 in the lisinopril
group and 2 in the losartan group receiving
corticosteroids
Buyse 2011
Methods Randomised controlled trial
Participants 21 boys with DMD aged 8 to 16 years with subclinical cardiomyopathy defined by the
presence of reduced radial strain measurements in the postero-lateral segments of the left
ventricular wall on echocardiography
Mean age: idebenone 10.8 (SD 1.9); placebo 13.4 (SD 2.1)
Corticosteroid users: idebenone 5; placebo 8
Other inclusion criteria:
If on chronic corticosteroids and/or cardiac medications (beta-blockers or diuretics, at
stable doses for ≥ 6 months and ≥ 3 months, respectively and during the trial
Able to perform “reproducible upper limb quantitative muscle testing”
Exclusion criteria:
Use of ACE inhibitors, coenzyme Q10, idebenone, creatine, glutamine, oxatomide or
any herbal medicines within the last 6 months
Symptomatic cardiomyopathy or heart failure
LVFS (M mode) < 20% and/or ejection fraction < 40%, previous history or presence of
41Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated
cardiomyopathy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Buyse 2011 (Continued)
ventricular arrhythmias and significant concomitant illness
Interventions Idebenone 150 mg (N = 13) or placebo (N = 8)
Outcomes Primary: change in peak systolic radial strain in left ventricular inferolateral wall
Funding sources Santhera Pharmaceuticals
Declarations of interest 1 author an employee and stockholder of funding company which manufactures
idebenone; 2 authors “co-inventors of relevant patent applications”
Notes NCT00654784
Enrollment October 2005 to July 2006; follow-up until August 2007
Location: Leuven, Belgium
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A list of block randomisation numbers and correspond-
ing treatment numbers was computer generated by a
third party
Allocation concealment (selection bias) Low risk Eligible patients were randomised in a double blind fash-
ion and allocated without further stratification in a 2:1
ratio to receive idebenone or matching placebo
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts and specified number of patients with
no data available for end of treatment (placebo = 1,
idebenone = 2)
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias High risk The idebenone treated group were older than the placebo
group
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Cittadini 2003
Methods Randomised, double-blind, parallel-group (pilot study)
Participants 6 participants with DMD (8 to 19 years) and 10 participants with BMD (24 to 55 years)
with documented cardiac involvement
Mean age: DMD 13 years (SD 2); BMD 39 years (SD 3)
Background therapy unchanged in all participants
DMD or BMD diagnosis biopsy-confirmed; no other inclusion/exclusion criteria spec-
ified
Interventions Weekly growth hormone 0.23 mg/kg/week (DMD) and 0.07 mg/kg/week (BMD)
Placebo
Self-injected, subcutaneously at bedtime for 3 months
Outcomes Hormonal measures, ECG (cardiomyopathic index), ECG cardiomyopathic index (QT-
PQ ratio), echocardiography (M-mode, 2D and echo-Doppler), measures of left ven-
tricular size and function, timed function tests ((timed Gowers’ manoeuvre, time to
climb 4 standard stairs, timed 10 metre walk, and ’dynamic index’). Pulmonary function
measures comprised forced vital capacity (FVC), maximal voluntary ventilation, and
maximal expiratory pressure
Funding sources Grant from Telethon
Declarations of interest None given
Notes Dates of enrollment and follow-up not reported
Location: Italy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stated to be randomised butmethodof ran-
domisation not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo-controlled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators performing the echocardio-
graphs were blind to treatment allocations
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The manuscript did not mention if there
were any dropouts or withdrawals
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Cittadini 2003 (Continued)
Selective reporting (reporting bias) High risk The report provided no numerical data
for left ventricular mass index, end-sys-
tolic stress and ejection fraction outcomes,
which were presented graphically
Other bias High risk The age range of participants was wide and
ranged from 8-19 years for DMD and 24-
55 years for BMD and they were all taking
multiple other treatments for cardiomy-
opathy
BMD: ’background’ therapy including
fosinopril 20 mg/day to 30 mg/day
(ACE inhibitor), warfarin, magnesium
supplements, pidolatum, antioxidants (vi-
tamins E, C, glutathione, ubiquinone),
furosemide, deflazacort.One participant in
each group was also receiving digoxin and
amiodarone
All DMD participants were receiving de-
flazacort, fosinopril and antioxidants (vita-
min E, glutathione and ubiquinone)
Duboc 2005
Methods Double-blind RCT
Participants 57 children with genetically proven DMD aged 9.5-13 years with normal cardiac exam-
ination, and radionucleotide LVEF > 55%
Age range: 9.5 to 13 years
Mean age in years: perindopril 10.7 (SD 1.2); placebo 10.6 (SD 1.2)
Baseline LVEF%: perindopril 65.0% (SD 5.5); placebo 65.4% (SD 5.5)
Other inclusion criteria:
Toleration of a 1 mg test dose of perindopril
Systolic BP ≥ 80 mmHg supine, > 70 mmHg sitting
Exclusion criteria:
Treatment with cardioactive drugs
Blood urea nitrogen > 7 mmol/L
Contraindications to ACE inhibitor therapy
Interventions Perindopril 2 mg to 4 mg day for 3 years (N = 28)
Placebo (N = 29)
Outcomes Reduction in mean LVEF via radionuclide ventriculography, clinical data and tolerance
of study drug
Funding sources Grants from French Association Against Myopathies and from Servier Laboratories
Declarations of interest None declared. One trial author affiliated to Servier Laboratories
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Duboc 2005 (Continued)
Notes Dates of enrollment and follow-up not reported
Location: 10 sites in France
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Radionuclide ventriculography was analysed by 2 experts
blinded to study data
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Experts blinded to study data
Incomplete outcome data (attrition bias)
All outcomes
Low risk One patient did not complete phase 1
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk None identified
Raman 2014
Methods Multicentre, randomised, double-blind, placebo-controlled trial
Participants 42 boys or young men over 7 years of age with DMD
Median age in years: eplerenone 14.5 ( IQR12.0 to 18.5); placebo 15.0 (IQR 11.0 to
19.0)
DMD diagnosis by mutation analysis or classic phenotypic features
Inclusion criteria:
Myocardial damage in one or more left ventricular segments (on late gadolinium en-
hancement)
Preserved left ventricular systolic function (EF ≥ 45%) measured by cine cardiac MRI
Current ACE inhibitor or ARB therapy
Exclusion criteria:
MRI-incompatible implants
Severe claustrophobia
Allergy to gadolinium contrast
Treatments: eplerenone or spironolactone, potassium-sparing diuretics, recent experi-
mental treatments (within defined period), CYP3A4 strong inhibitors
Scheduled surgery carrying risk of adverse events
Baseline serum potassium over 5.5 mmol/L
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Raman 2014 (Continued)
Interventions Eplerenone 25 mg orally alternate days for the 1st month, then daily if the serum
potassium (K+) concentration remained ≤ 5.5 mmol/L (N = 20)
Placebo (N = 22)
Outcomes Primary: change in left ventricular circumferential strain from baseline to 12 months
Secondary:
• Change in left ventricular circumferential strain from baseline to 6months
• Changes in LVEF%
• Myocardial damage, by extent of late gadolinium enhancement at 6 and 12
months
• Biomarkers: serum creatine kinase-MB (CK-MB), troponin-1 and osteopontin
• Adverse events, including admission to hospital for heart failure, cardiac
arrhythmia, death and serum K+ > 5.5 mmol/L
Funding sources BallouSkies, Parent Project for Muscular Dystrophy, US National centre for advancing
translational studies and National Institutes of Health. Pfizer supplied active drug and
placebo. Funding sources stated to have no involvement in study planning, execution,
data analysis or report writing
Declarations of interest Quote: “The authors were not paid to write this article by a pharmaceutical company or
other agency.”
SVR declared “research support via an institutional agreement from Siemens, one of
two manufacturers of MRI equipment used in this study; this company had no active
involvement in the study.”
“Although study drug and matching placebo were obtained from Pfizer Pharmaceuticals,
Pfizer had no active involvement in the study”
Other authors declared no competing interests.
Notes Registered on ClinicalTrials.gov as NCT01521546
Enrolment and follow-up visits conducted between 3 March 2012 and 1 July 2014
Location: 3 sites in US
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised computer-generated randomi-
sation with block sizes of 4 and 6
Allocation concealment (selection bias) Low risk Quote: “only the study statistician and
the investigational pharmacist had the ran-
domisation assignments”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study personnel and participants were
blinded
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Raman 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study personnel and participants were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete trial profile
Selective reporting (reporting bias) High risk All outcomes reported. 12-month changes
from baseline for cardiac measures shown
graphically. The report gives the total num-
ber of analysable examinations but not
numbers for each study visit (baseline, 6
and 12 months); therefore, number of par-
ticipants providing data for outcomes at
each time point is unclear
Other bias High risk None identified. Participants were receiv-
ing many concomitant medications:
concomitant ACE inhibitors (18 in
eplerenone group; 20 in placebo group)
. 8 in the eplerenone group and 9 in
the placebo group were also taking beta-
blockers and 2 regular furosemide. Other
concomitant non-cardiac medications in-
cluded: multivitamins, coenzyme Q10, vi-
tamin D, calcium supplements, proton
pump inhibitors and corticosteroids
We judged the risk of bias as high as it
is not possible to determine whether con-
comitant therapy confounded the results
ACE: angiotensin converting enzyme; ARB: angiotensin receptor blockers; BMD: Becker muscular dystrophy; DMD: Duchenne
muscular dystrophy;ECG: echocardiogram;FVC: forced vital capacity;LVEF: left ventricular ejection fraction;LVFS: left ventricular
fractional shortening;MRI; magnetic resonance imaging; NCH: Nationwide Children’s Hospital.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bushby 2014 No cardiac outcome measures
Duboc 2007 Non-randomised study
Folkers 1985 Non-randomised study
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Ishikawa 1995 Non-randomised study
Kajimoto 2006 Non-randomised open-label study
Matsumura 2010 Non-randomised study
Mendell 2013 No cardiac outcome measures
Rhodes 2008 Non-randomised open-label study
Voit 2014 No cardiac outcome measures
Characteristics of studies awaiting assessment [ordered by study ID]
EUCTR2008-007236-18-IT
Methods Randomised, parallel-group trial
Participants Adults and children (over 2 years of age) with BMD or DMD and normal baseline cardiac function
Inclusion criteria:
Immunohystochemical and molecular diagnosis of DMD and BMD
No evidence of clinical cardiomyopathy, i.e. no cardiac symptoms, normal ECG, normal 2D-echocardiography with
normal systolic, (left ventricular ejection fraction ≥ 55%, right ventricular ejection fraction ≥ 45% and absence of
regional wall motion abnormalities (wall motion score index = 1), and diastolic function
Informed consent obtained, able and willing to undergo procedures
Exclusion criteria:
Cardiological therapy (ACE inhibitors, ARBs or beta-blockers)
Contraindications to carvedilol or ramipril
ECG anomalies: in DMD, tall R waves in the right precordial leads with an abnormal RS ratio a deep and narrow
Q wave greater than 4 mm over leads I V5 and V6; in BMD, ECG changes suggestive of ischaemic heart disease left
bundle-branch block atrial flutter, fibrillation, ventricular arrhythmias, any degree of atrioventricular block and left
ventricular hypertrophy
In BMD, hypertension and valvular heart disease (other than trivial)
Ventilatory assistance
Systolic and/or diastolic dysfunction detected by 2D-echocardiography
Contraindications to cardiac MRI (including any history of claustrophobia)
Renal failure, even mild
Concomitant steroid therapy allowable
Interventions Carvedilol 6.25 mg, oral
Ramipril 2.5 mg, oral
Outcomes Primary: left ventricular ejection fraction, systolic and diastolic left ventricular volumes, late gadolinium enhancement
(as a quantitative dimension) and ultrasonic tissue characterisation values
Notes Prematurely ended 20 June 2013. ICTRP record states no results available - to be confirmed before probable exclusion
48Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated
cardiomyopathy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Leung 2014
Methods Single-centre, randomised, double-blind, placebo-controlled trial
Participants 20 adults (≥ 15 years) with DMD (defined as absent dystrophin staining on muscle biopsy or a dystrophin mutation
predictive of the Duchenne phenotype on genetic testing) and cardiomyopathy
Inclusion criteria:
Ejection fraction≤ 45%, concurrent use of an ACE inhibitor or ARB for≥ 3months at unchanging dose, unchanged
beta-blocker or corticosteroid dosing for 3 months
Exclusion criteria:
Contraindications to MRI, implantable cardiac devices, frequent cardiac arrhythmia, hereditary retinal disorders,
bleeding disorders, a systolic blood pressure ≤ 85 mmHg or lower, stage 4 or 5 renal failure, active tobacco use,
concurrent use of nitrates, alpha-adrenergic receptor blockers, or phosphodiesterase inhibitors
Interventions Sildenafil (20 mg, 3 times daily) (N = 10)
Placebo (N = 10)
Treatment duration: 6 months
Outcomes Primary: change in left ventricular end-systolic volume on cardiac MRI
Secondary: cardiac measures (end-systolic, end-diastolic, and stroke volumes, left ventricular myocardial mass, and
ejection fraction), skeletal muscle function (grip and pinch strength using hand-held dynamometry), forced vital
capacity, quality of life (Short-Form 36 Health Survey (SF-36) and Individualized Neuromuscular Quality of Life
Questionnaire (INQoL)) and adverse events
Notes ClinicalTrials.gov: NCT01168908
Enrollment stopped early for harm (number experiencing ≥10% increase in LVESV while taking sildenafil)
Salehi 2017
Methods Randomised, double-blind, placebo-controlled trial
Participants Report states: “Children aged 6 to 10 years old were enrolled in a study in which Duchenne muscular dystrophy
(DMD) was diagnosed and approved in them by DNA analysis and muscle biopsy (quadriceps or biceps)”
Mean age (SD) in years: coenzyme Q10 8.9 (1.7); placebo 8.6 (1.4)
Exclusion criteria:
Confirmed or suspected heart disease
Other concomitant illness
Taking herbal medicine, vitamins or enzymes
Arrhythmia on ECG
’Inappropriate view’ in echocardiography
Interventions Coenzyme Q10 (N = 12)
Placebo (N = 13)
Treatment duration: 6 months
Outcomes Myocardial performance index
Notes Location: Tehran, Iran
Dates: February 2013 to 2015
Iranian Clinical Trials Registry number: IRCT2015070223018N1
The report suggests that the trial included both male and female participants and describes participants as “suspected
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Salehi 2017 (Continued)
of DMD”
ACE inhibitor: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; BMD:Beckermuscular dystrophy;DMD:
Duchenne muscular dystrophy; ECG: electrocardiograph; MRI: magnetic resonance imaging
Characteristics of ongoing studies [ordered by study ID]
FOR-DMD 2012
Trial name or title Finding the optimum regimen for Duchenne muscular dystrophy (FOR-DMD)
Methods Randomised, parallel-assignment, quadruple-blind (participant, care provider, investigator and outcomes
assessor), phase 3 trial
Participants Boys with DMD between 4 and 7 years old
Interventions Experimental (3 groups):
daily prednisone (0.75 mg/kg/day);
intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off )
daily deflazacort (0.9 mg/kg/day) for 36 to 60 months
Outcomes Cardiac function monitored by trans-thoracic echocardiogram and 12-lead ECG was a secondary outcome.
Function was categorised as: normal, abnormal but not clinically significant, and abnormal and clinically
significant. The earliest definite, echo-detectable impairment of left ventricular functionwas defined as ejection
fraction < 55% and/or fractional shortening < 28%. Time frame: 1 to 3 months prior to the baseline visit,
then every 2 years to the age of 10 years, and annually thereafter or at the onset of cardiac signs and symptoms
and the year 3 visit
The primary outcome combined FVC, time to stand (log-transformed) and participant/parent satisfaction
with treatment. Other outcomes included timed function tests, range of movement at the ankle, regimen
tolerance, adverse events, and quality of life
Starting date January 2013 (estimated primary completion date October 2019)
Contact information Principal Investigator: Robert Griggs, MD, Professor of Neurology, University of Rochester
Notes
ISRCTN50395346
Trial name or title A double-blind randomised multi-centre, placebo-controlled trial of combined angiotensin converting en-
zyme-inhibitor and beta-blocker therapy in preventing the development of cardiomyopathy in genetically
characterised males with Duchenne muscular dystrophy without echo-detectable left ventricular dysfunction
Methods Double-blind, randomised, multicentre, placebo-controlled trial
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ISRCTN50395346 (Continued)
Participants Boys aged 7 to 12 years with genetically confirmed DMD and normal left ventricular function on trans-
thoracic echocardiography
Interventions Perindopril 2 mg/bisoprolol 1.25 mg or placebo for the 1-month run-in period
Perindopril 4 mg/bisoprolol 2.5 mg or placebo for the remainder of the trial
2-year treatment period. Follow-up period up to 60 months.
Outcomes Primary outcome: change from baseline in left ventricular ejection fraction measured by Simpson’s biplane
disk method, after a minimum of 2 years’ active treatment or placebo
Similar comparisons performed for parameters of left ventricular end-systolic volume and wall motion index
Secondary endpoints: death from any cause, development of symptoms and signs of congestive cardiac failure,
and sufficient objective deterioration in cardiac function without symptoms to make continued placebo
therapy unethical
Starting date September 2007
Contact information John Bourke, Freeman Hospital, Newcastle upon Tyne, UK
Notes
NCT00606775
Trial name or title The preventive efficacy of carvedilol on cardiac dysfunction in Duchenne muscular dystrophy
Methods Randomised, parallel-assignment, open-label, phase 4 trial
Participants Boys and men with DMD, aged 8 to 45 years
Interventions Carvedilol 2.5 mg/day to 5 mg/day
No intervention
Outcomes Primary outcome: suppression of minor cardiac damage indicated as elevation of plasma cardiac troponin I
(time frame: 2 years)
Secondary outcomes: left ventricular function deterioration assessed by echocardiography, in-hospital mor-
tality for cardiac dysfunction, in-hospital mortality for any cause, overall mortality (time frame: 5 years)
Starting date December 2007
Contact information Principal Investigator: Takao Nishizawa, Department of Cardiology, Nagoya University Graduate School of
Medicine
Notes
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NCT00819845
Trial name or title Ramipril versus carvedilol in Duchenne and Becker patients
Methods Randomised, parallel-assignment, open-label, phase 4 trial
Participants Males aged 2 to 45 years with Immunohistochemical and molecular diagnosis of BMD or DMD
Interventions Carvedilol
Ramipril
Outcomes Primary outcome: left ventricular ejection fraction, systolic and diastolic left ventricular volumes and late
gadolinium enhancement (LGE, as a quantitative measure) detected byMRI andmyocardial ultrasound tissue
characterisation (UTC) data by echocardiography (time frame: 1 year)
Secondary outcome: prevalence of LGE in DMD and BMD, the effects of pharmacological therapy both on
LGE evolution and myocardial UTC analysis (time frame: 1 year)
Starting date December 2008
Contact information Principal Investigator: Vincenzo Giglio, MD, PhD Uildm, Rome
Notes
NCT01126697
Trial name or title Clinical trial of coenzyme Q10 and lisinopril in muscular dystrophies
Methods Randomised, factorial assignment, open-label, phase 2 or 3 trial
Participants 120 participants aged 8 and above with DMD, BMD, or autosomal recessive limb-girdle muscular dystrophy
(specifically 2C-2F and 2I) without clinical cardiac symptoms
Interventions Participants randomised to 1 of 4 arms: coenzyme Q10 alone, lisinopril alone, coenzyme Q10 and lisinopril,
or no study medication
Outcomes Primary outcome: myocardial performance index (time frame: every 6 months)
Starting date February 2010
Contact information Cooperative International Neuromuscular Research Group
Notes
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NCT01350154
Trial name or title Effect of modulating the nNOS system on cardiac, muscular and cognitive function in Becker muscular
dystrophy patients
Methods Randomised, cross-over assignment, quadruplemasking (participant, care provider, investigator and outcomes
assessor), phase 2 trial
Participants Males aged 18 years to 80 years with BMD and an established deficiency in muscular content of nNOS
protein
Interventions Participants will receive 4 weeks of either sildenafil or placebo with a 2-week washout period between treat-
ments
Outcomes Primary outcomes were measured as the difference between treatment and placebo groups in the changes
betweenbaseline and4weeks in: handgrip testwith concomitant ultrasound brachial artery flowmeasurement;
resting cardiac end-diastolic volume measured by MRI; cerebrovascular reactivity to CO2 inhalation and
finger stimulation measured by blood oxygen level-dependent functional MRI (BOLD fMRI); and cognitive
function measured by the Cambridge Neuropsychological Test Automated Battery (CANTAB)
Starting date November 2011
Contact information Neuromuscular Clinic and Research Unit, Department of Neurology, Rigshospitalet, Copenhagen, Denmark
Notes
NCT01648634
Trial name or title Nebivolol for the prevention of left ventricular systolic dysfunction in patients with Duchenne muscular
dystrophy (NEBIDYS)
Methods Randomised, parallel-assignment, double-blind, phase 3 trial
Participants Boys aged 10 years to 15 years with genetically proven DMD
Interventions Nebivolol
Placebo
Outcomes Primary outcome: left ventricular systolic dysfunction
Secondary outcomes: right ventricular ejection fraction, N-terminal pro-brain natriuretic peptide (NT-
ProBNP), left ventricular dysfunction, hospitalisations, mortality
Starting date February 2012
Contact information Principal Investigator: Henri-Marc BECANE, Armand Trousseau Hospital
Notes
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NCT02354352
Trial name or title Therapeutic potential for aldosterone inhibition in Duchenne muscular dystrophy
Methods Randomized, single group assignment, quadruple-blind (participant, care provider, investigator, outcomes
assessor)
Participants Boys 7 years and older with DMD with a left ventricular ejection fraction ≥ 45% (+/-5%) by clinically-
acquired echocardiography, nuclear scan or cardiac MRI done within 2 weeks of enrollment
Interventions Eplerenone (one 50 mg capsule by mouth once daily for 12 months)
Spironolactone (one 50 mg capsule by mouth once daily for 12 months)
Outcomes Primary outcome: left ventricular strain at 12 months
Secondary outcomes: FVC, muscle injury blood biomarkers
Starting date January 2015
Contact information Principal investigator: Subha Raman, Ohio State University
Notes
NCT02432885
Trial name or title Myocardial fibrosis progression in Duchenne and Becker muscular dystrophy - ACE inhibitor therapy trial
Methods Randomised, parallel-assignment, open-label, phase 3 trial
Participants Male and female participants aged 6 years and older, with biopsy-proven BMD or DMD
Interventions Enalapril (ACE inhibitor) up to 20 mg twice daily
Placebo
Outcomes Primary outcome: quantitative myocardial fibrosis by cardiacMRI in patients with andwithout ACE inhibitor
therapy
Secondary outcome: specific genetic mutations as predictors of cardiac involvement
Time frame: 2 years
Starting date June 2009
Contact information Principal Investigator: Carlos E Rochitte, Heart Institute, University of Sao Paulo Medical School
Notes
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NCT02485938
Trial name or title HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) (HOPE)
Methods Randomised, parallel-assignment, open-label trial
Participants Male participants aged 12 years and over with cardiomyopathy secondary to DMD
Interventions Participants randomised in a 1:1 manner to either intracoronary infusion of CAP-1002 in 3 coronary arteries
supplying the 3 major cardiac territories of the left ventricle of the heart (anterior, lateral, inferior/posterior)
or usual care
In the active treatment arm, all 3 major cardiac territories will be treated (infused) during a single procedure
in an open-label fashion
Outcomes Primary outcome: safety and tolerability composite of CAP-1002 will be established by summaries of the
occurrence of changes in coronary blood flow events, major cardiac events, laboratory assessments, vital signs,
physical examination, electrocardiograph, and the occurrence of major adverse events (time frame: 72 hours
post infusion)
Secondary outcomes: cardiac MRI, functional composite outcome, quality of life composite outcome,
biomarkers (time frame: 12 months)
Starting date January 2016
Contact information Principal Investigator: John L Jefferies, MD, MPH Children’s Hospital Medical Center, Cincinnati
Study Director: Deborah Ascheim, MD Capricor Inc.
Notes
NCT03340675
Trial name or title Oral ifetroban in subjects with Duchenne muscular dystrophy (DMD)
Methods Randomised, placebo-controlled, parallel-assignment, double-blind, phase 2 trial
Participants Males aged 7 years and older with the diagnosis of DMD (phenotype consistent with DMD and either
positive genotype, first degree relative with positive genotype, or confirmatory muscle biopsy)
Interventions Oral ifetroban low dose
Oral ifetroban high dose
Placebo
Administration: once daily for 12 months
Outcomes Primary outcome: incidence of treatment-emergent adverse events (safety and tolerability) (over 12 months)
Secondary outcomes: pharmacokinetics (day 0 and day 7), change (from baseline to 12 months) in left
ventricular ejection fraction, change from baseline in pulmonary function, change from baseline in quality
of life
Starting date November 2018
Contact information Sponsors and collaborators: Cumberland Pharmaceuticals, Vanderbilt University Medical Center
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NCT03340675 (Continued)
Notes
NCT03406780
Trial name or title A study of CAP-1002 in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy
(HOPE-2)
Methods Randomised, placebo-controlled, parallel-assignment, quadruple-blind (participant, care provider, investiga-
tor, outcomes assessor)
Participants Male participants, 10 years or older with genetically confirmed DMD, reduced upper arm strength, reduced
ability to walk or run (if ambulatory), having received at least 12 months’ treatment with corticosteroids at a
stable dose for at least 6 months. Exclusion criteria includes ejection fraction < 35%
Interventions CAP-1002 (cardiosphere-derived cells (CDCs)) 150 million CDCs via intravenous infusion every 3 months
on 4 occasions
Placebo intravenous infusions on same schedule
Outcomes Primary outcome: change in the mid-level (elbow) dimension of the Performance of the Upper Limb (PUL)
(time frame: 12 months)
Secondary outcomes: change in mid-level (elbow) dimension of the PUL (time frame: 3, 6, and 9 months),
change in regional systolic left ventricular wall thickening as assessed by cardiac MRI (time frame: months 6
and 12)
Starting date April 2018
Contact information Brian Fedor, Capricor Inc.; HOPE-2@capricor.com
Notes
NCT03439670
Trial name or title A study to assess the efficacy and safety of vamorolone in boys with Duchenne muscular dystrophy (DMD)
Methods Randomized, parallel group, placebo and active-controlled, quadruple-blind (participant, care provider, in-
vestigator, outcomes assessor)
Participants Boy aged 4 to 7 years old with confirmed diagnosis of DMD
Interventions Vamorolone, orally at 2.0 mg/kg and 6.0 mg/kg
Prednisone 0.75 mg/kg/day
Placebo
Duration of treatment: 24 weeks
Outcomes Primary outcomes: muscle function; body size as measured by body mass index (time frame 24 weeks)
Secondary outcomes: cardiac function (measured by ECG (week 12, week 24, week 40, week 48), 2-D
echocardiogram (week 24, week 48)); treatment-emergent adverse effects; multiple safety measures; multiple
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NCT03439670 (Continued)
efficacy outcomes
Starting date June 2018
Contact information Andrea Smith: asmith@trinds.com
Notes
ACE inhibitor: angiotensin converting enzyme inhibitor; BMD: Becker muscular dystrophy; DMD: Duchenne muscular dystrophy;
ECG: electrocardiogram; FVC: forced vital capacity; MRI: magnetic resonance imaging
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D A T A A N D A N A L Y S E S
Comparison 1. Prophylactic perindopril versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cardiac function (number of
participants with ejection
fraction < 45%) (3 years)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 2. Lisinopril versus losartan
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cardiac function (ejection
fraction) (1 year)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2 Adverse events 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 3. Idebenone versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cardiac function (change in
fractional shortening) (1 year)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2 Cardiac function (change in
LVEF)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3 Cardiac function (change in
peak systolic radial strain in
left ventricular lateral wall
segments)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4 Cardiac function (change in
systolic radial strain rate left
ventricular inferolateral wall)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5 Peak systolic longitudinal strain 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Left ventricle lateral mid 1 17 Mean Difference (IV, Fixed, 95% CI) -5.0 [-10.61, 0.61]
5.2 Left ventricle lateral apex 1 14 Mean Difference (IV, Fixed, 95% CI) 1.30 [-4.47, 7.07]
5.3 Left ventricle lateral basal 1 16 Mean Difference (IV, Fixed, 95% CI) 4.5 [-1.81, 10.81]
6 Peak systolic longitudinal strain 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 Interventricular septum
mid
1 19 Mean Difference (IV, Fixed, 95% CI) 0.80 [-6.47, 8.07]
6.2 Interventricular septum
apex
1 19 Mean Difference (IV, Fixed, 95% CI) -3.10 [-13.02, 6.82]
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6.3 Interventricular septum
basal
1 18 Mean Difference (IV, Fixed, 95% CI) -1.70 [-6.93, 3.53]
7 Peak systolic longitudinal strain 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Right ventricle apex 1 16 Mean Difference (IV, Fixed, 95% CI) -3.80 [-14.73, 7.13]
7.2 Right ventricle basal 1 17 Mean Difference (IV, Fixed, 95% CI) -5.0 [-18.19, 8.19]
8 Global left ventricular
functioning
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 Cardiac index 1 18 Mean Difference (IV, Fixed, 95% CI) 0.1 [-0.75, 0.95]
8.2 Cardiac output 1 18 Mean Difference (IV, Fixed, 95% CI) 0.6 [-0.33, 1.53]
Comparison 4. Eplerenone versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cardiac function - change
(decline) in left ventricular
strain (baseline to 6 months)
Other data No numeric data
2 Cardiac function - change
(decline) in left ventricular
strain (baseline to 12 months)
Other data No numeric data
3 Cardiac function (change in
LVEF) (baseline to 6 months)
Other data No numeric data
4 Cardiac function (change in
LVEF) from baseline to 12
months
Other data No numeric data
5 Change in size of metabolically
abnormal areas of myocardium
(baseline to 6 months)
Other data No numeric data
6 Change in size of metabolically
abnormal areas of myocardium
(baseline to 12 months
Other data No numeric data
7 Adverse events 1 42 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.02, 8.48]
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Analysis 1.1. Comparison 1 Prophylactic perindopril versus placebo, Outcome 1 Cardiac function (number
of participants with ejection fraction < 45%) (3 years).
Review: Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy
Comparison: 1 Prophylactic perindopril versus placebo
Outcome: 1 Cardiac function (number of participants with ejection fraction < 45%) (3 years)
Study or subgroup Favours perindopril Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Duboc 2005 1/28 1/29 1.04 [ 0.07, 15.77 ]
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours perindopril Favours placebo
Analysis 2.1. Comparison 2 Lisinopril versus losartan, Outcome 1 Cardiac function (ejection fraction) (1
year).
Review: Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy
Comparison: 2 Lisinopril versus losartan
Outcome: 1 Cardiac function (ejection fraction) (1 year)
Study or subgroup Lisinopril Losartan
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Allen 2013 7 54.6 (5.19) 9 55.2 (7.19) -0.60 [ -6.67, 5.47 ]
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours losartan Favours lisinopril
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Analysis 2.2. Comparison 2 Lisinopril versus losartan, Outcome 2 Adverse events.
Review: Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy
Comparison: 2 Lisinopril versus losartan
Outcome: 2 Adverse events
Study or subgroup Lisinopril Losartan Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Allen 2013 0/12 2/10 0.17 [ 0.01, 3.16 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours lisinopril Favours losartan
Analysis 3.1. Comparison 3 Idebenone versus placebo, Outcome 1 Cardiac function (change in fractional
shortening) (1 year).
Review: Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy
Comparison: 3 Idebenone versus placebo
Outcome: 1 Cardiac function (change in fractional shortening) (1 year)
Study or subgroup Idebenone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Buyse 2011 13 1.4 (4.1) 8 1.6 (2.6) -0.20 [ -3.07, 2.67 ]
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours placebo Favours idebenone
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Analysis 3.2. Comparison 3 Idebenone versus placebo, Outcome 2 Cardiac function (change in LVEF).
Review: Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy
Comparison: 3 Idebenone versus placebo
Outcome: 2 Cardiac function (change in LVEF)
Study or subgroup Idebenone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Buyse 2011 12 -1.9 (9.8) 7 0.4 (5.5) -2.30 [ -9.18, 4.58 ]
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours placebo Favours idebenone
Analysis 3.3. Comparison 3 Idebenone versus placebo, Outcome 3 Cardiac function (change in peak systolic
radial strain in left ventricular lateral wall segments).
Review: Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy
Comparison: 3 Idebenone versus placebo
Outcome: 3 Cardiac function (change in peak systolic radial strain in left ventricular lateral wall segments)
Study or subgroup Idebenone Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
Buyse 2011 11 17.3 (13.1) 7 7.5 (12) 9.80 [ -1.99, 21.59 ]
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours placebo Favours idebenone
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Analysis 3.4. Comparison 3 Idebenone versus placebo, Outcome 4 Cardiac function (change in systolic
radial strain rate left ventricular inferolateral wall).
Review: Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy
Comparison: 3 Idebenone versus placebo
Outcome: 4 Cardiac function (change in systolic radial strain rate left ventricular inferolateral wall)
Study or subgroup Idebenone Control
Mean
Difference Weight
Mean
Difference
N
Mean(SD)[per
second] N
Mean(SD)[per
second] IV,Fixed,95% CI IV,Fixed,95% CI
Buyse 2011 11 0.5 (0.6) 7 0 (0.9) 0.50 [ -0.26, 1.26 ]
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours placebo Favours idebenone
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Analysis 3.5. Comparison 3 Idebenone versus placebo, Outcome 5 Peak systolic longitudinal strain.
Review: Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy
Comparison: 3 Idebenone versus placebo
Outcome: 5 Peak systolic longitudinal strain
Study or subgroup Idebenone Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Left ventricle lateral mid
Buyse 2011 10 -4.1 (7.1) 7 0.9 (4.7) 100.0 % -5.00 [ -10.61, 0.61 ]
Subtotal (95% CI) 10 7 100.0 % -5.00 [ -10.61, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.081)
2 Left ventricle lateral apex
Buyse 2011 9 1.4 (6.8) 5 0.1 (4.2) 100.0 % 1.30 [ -4.47, 7.07 ]
Subtotal (95% CI) 9 5 100.0 % 1.30 [ -4.47, 7.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
3 Left ventricle lateral basal
Buyse 2011 9 1.1 (8.7) 7 -3.4 (3.7) 100.0 % 4.50 [ -1.81, 10.81 ]
Subtotal (95% CI) 9 7 100.0 % 4.50 [ -1.81, 10.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Chi2 = 5.20, df = 2 (P = 0.07), I2 =62%
-20 -10 0 10 20
Favours placebo Favours idebenone
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Analysis 3.6. Comparison 3 Idebenone versus placebo, Outcome 6 Peak systolic longitudinal strain.
Review: Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy
Comparison: 3 Idebenone versus placebo
Outcome: 6 Peak systolic longitudinal strain
Study or subgroup Idebenone Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Interventricular septum mid
Buyse 2011 12 2.7 (8.3) 7 1.9 (7.5) 100.0 % 0.80 [ -6.47, 8.07 ]
Subtotal (95% CI) 12 7 100.0 % 0.80 [ -6.47, 8.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
2 Interventricular septum apex
Buyse 2011 12 -1.2 (7.8) 7 1.9 (12) 100.0 % -3.10 [ -13.02, 6.82 ]
Subtotal (95% CI) 12 7 100.0 % -3.10 [ -13.02, 6.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
3 Interventricular septum basal
Buyse 2011 11 -2.3 (6.5) 7 -0.6 (4.8) 100.0 % -1.70 [ -6.93, 3.53 ]
Subtotal (95% CI) 11 7 100.0 % -1.70 [ -6.93, 3.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 0.47, df = 2 (P = 0.79), I2 =0.0%
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Analysis 3.7. Comparison 3 Idebenone versus placebo, Outcome 7 Peak systolic longitudinal strain.
Review: Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy
Comparison: 3 Idebenone versus placebo
Outcome: 7 Peak systolic longitudinal strain
Study or subgroup Idebenone Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Right ventricle apex
Buyse 2011 10 -3.7 (14) 6 0.1 (8.3) 100.0 % -3.80 [ -14.73, 7.13 ]
Subtotal (95% CI) 10 6 100.0 % -3.80 [ -14.73, 7.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 Right ventricle basal
Buyse 2011 10 -7.6 (9.8) 7 -2.6 (15.8) 100.0 % -5.00 [ -18.19, 8.19 ]
Subtotal (95% CI) 10 7 100.0 % -5.00 [ -18.19, 8.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
-20 -10 0 10 20
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Analysis 3.8. Comparison 3 Idebenone versus placebo, Outcome 8 Global left ventricular functioning.
Review: Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy
Comparison: 3 Idebenone versus placebo
Outcome: 8 Global left ventricular functioning
Study or subgroup Idebenone Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Cardiac index
Buyse 2011 11 -0.1 (0.9) 7 -0.2 (0.9) 100.0 % 0.10 [ -0.75, 0.95 ]
Subtotal (95% CI) 11 7 100.0 % 0.10 [ -0.75, 0.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
2 Cardiac output
Buyse 2011 11 0.1 (1.3) 7 -0.5 (0.7) 100.0 % 0.60 [ -0.33, 1.53 ]
Subtotal (95% CI) 11 7 100.0 % 0.60 [ -0.33, 1.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Chi2 = 0.61, df = 1 (P = 0.44), I2 =0.0%
-2 -1 0 1 2
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Analysis 4.1. Comparison 4 Eplerenone versus placebo, Outcome 1 Cardiac function - change (decline) in
left ventricular strain (baseline to 6 months).
Cardiac function - change (decline) in left ventricular strain (baseline to 6 months)
Study Eplerenone (mean) SD Placebo (mean) SD P value
Raman 2014 0.84% 2.68 0.38% 2.56 0.602
Analysis 4.2. Comparison 4 Eplerenone versus placebo, Outcome 2 Cardiac function - change (decline) in
left ventricular strain (baseline to 12 months).
Cardiac function - change (decline) in left ventricular strain (baseline to 12 months)
Study Eplerenone
(median)
IQR Placebo (median) IQR P value
Raman 2014 1·0% 0·3 to −2·2 2·2% 1·3 to −3·1 0·020
67Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated
cardiomyopathy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.3. Comparison 4 Eplerenone versus placebo, Outcome 3 Cardiac function (change in LVEF)
(baseline to 6 months).
Cardiac function (change in LVEF) (baseline to 6 months)
Study Eplerenone
(median)
IQR Placebo (median) IQR P value
Raman 2014 0% −3.8 to 4.0 1.0% −5.0 to 2.1 0.474
Analysis 4.4. Comparison 4 Eplerenone versus placebo, Outcome 4 Cardiac function (change in LVEF) from
baseline to 12 months.
Cardiac function (change in LVEF) from baseline to 12 months
Study Eplerenone
(median)
IQR Placebo (median) IQR P value
Raman 2014 −1·8% −2·9 to 6·0 −3·7% −10·8 to 1·0 0·032
Analysis 4.5. Comparison 4 Eplerenone versus placebo, Outcome 5 Change in size of metabolically
abnormal areas of myocardium (baseline to 6 months).
Change in size of metabolically abnormal areas of myocardium (baseline to 6 months)
Study Eplerenone (mean) SD Placebo (mean) SD P value
Raman 2014 −2% 6 4% 6 0.034
Analysis 4.6. Comparison 4 Eplerenone versus placebo, Outcome 6 Change in size of metabolically
abnormal areas of myocardium (baseline to 12 months.
Change in size of metabolically abnormal areas of myocardium (baseline to 12 months
Study Eplerenone
(median)
IQR Placebo (median) IQR P value
Raman 2014 −1% −6 to 3 −3% −5 to 4 > 0·999
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Analysis 4.7. Comparison 4 Eplerenone versus placebo, Outcome 7 Adverse events.
Review: Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy
Comparison: 4 Eplerenone versus placebo
Outcome: 7 Adverse events
Study or subgroup Eplerenone Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Raman 2014 0/20 1/22 100.0 % 0.37 [ 0.02, 8.48 ]
Total (95% CI) 20 22 100.0 % 0.37 [ 0.02, 8.48 ]
Total events: 0 (Eplerenone), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours eplerenone Favours placebo
A P P E N D I C E S
Appendix 1. Cochrane Neuromuscular Specialised Register (CRS) search strategy
#1 (duchenne or becker) NEAR5 dystroph* [REFERENCE] [STANDARD]
#2 dystrophinopath* or xldcm or “x linked dilated cardiomyopathy” [REFERENCE] [STANDARD]
#3 MeSH DESCRIPTOR Dystrophin WITH GE [REFERENCE] [STANDARD]
#4 #1 or #2 or #3 [REFERENCE] [STANDARD]
#5 cardiomyopathy or cardiomyopathies or “myocardial diseases” or “heart failure” [REFERENCE] [STANDARD]
#6 “cardiac protection” or “ventricular dilation” or “heart transplantation” [REFERENCE] [STANDARD]
#7 MeSH DESCRIPTOR Pacemaker, Artificial [REFERENCE] [STANDARD]
#8 artificial NEAR pacemaker [REFERENCE] [STANDARD]
#9 defibrillators or “electric countershock” or “cardiac resynchronisation” [REFERENCE] [STANDARD]
#10 “cardiac pacing” NEAR artificial [REFERENCE] [STANDARD]
#11 MeSH DESCRIPTOR Angiotensin-Converting Enzyme Inhibitors Explode All [REFERENCE] [STANDARD]
#12 MeSH DESCRIPTOR Calcium Channel Blockers Explode All [REFERENCE] [STANDARD]
#13 MeSH DESCRIPTOR Adrenergic beta-Antagonists Explode All [REFERENCE] [STANDARD]
#14 MeSH DESCRIPTOR Cardiotonic Agents Explode All [REFERENCE] [STANDARD]
#15 MeSH DESCRIPTOR Diuretics Explode All [REFERENCE] [STANDARD]
#16 MeSH DESCRIPTOR Oligonucleotides, Antisense Explode All [REFERENCE] [STANDARD]
#17 MeSH DESCRIPTOR Morpholines Explode All [REFERENCE] [STANDARD]
#18 (cardiac NEAR1 failure) or (cardiac NEAR1 protection) or (inotropic NEAR1 agent*) [REFERENCE] [STANDARD]
#19 (cardiac NEAR1 transplant*) or (cardiac NEAR3 complication*) [REFERENCE] [STANDARD]
#20 diuretic* or pacemaker or morpholino [REFERENCE] [STANDARD]
#21 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 [REFERENCE]
[STANDARD]
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#22 #4 and #21 [REFERENCE] [STANDARD]
#23 (#4 and #21) AND (INREGISTER) [REFERENCE] [STANDARD]
Appendix 2. CENTRAL (CRSO) search strategy
Search run on Mon 16 October 2017
#1 MESH DESCRIPTOR Muscular Dystrophies97
#2 MESH DESCRIPTOR Muscular Dystrophy, Duchenne68
#3 (duchenne NEAR dystrophy):TI,AB,KY300
#4 (becker NEAR dystrophy):TI,AB,KY45
#5 (dystrophinopathy or dystrophinopathies):TI,AB,KY21
#6 MESH DESCRIPTOR Dystrophin18
#7 (xldcm or “x linked dilated cardiomyopathy”):TI,AB,KY0
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7343
#9 MESH DESCRIPTOR Cardiomyopathies EXPLODE ALL TREES1399
#10 MESH DESCRIPTOR Cardiomyopathy, Dilated434
#11 MESH DESCRIPTOR Heart Failure EXPLODE ALL TREES5733
#12 “myocardial diseases”3
#13 (“cardiac protection” or “ventricular dilation”):TI,AB,KY92
#14 MESH DESCRIPTOR Angiotensin-Converting Enzyme Inhibitors EXPLODE ALL TREES5561
#15 MeSH descriptor Calcium Channel Blockers EXPLODE ALL TREES7997
#16 MESH DESCRIPTOR Adrenergic beta-Agonists EXPLODE ALL TREES8511
#17 MESH DESCRIPTOR Cardiotonic Agents EXPLODE ALL TREES5163
#18 MESH DESCRIPTOR Diuretics EXPLODE ALL TREES5730
#19 “Heart Transplant*”1059
#20 MESH DESCRIPTOR Pacemaker, Artificial EXPLODE ALL TREES610
#21 defibrillator or “electric countershock”):TI,AB,KY2671
#22 (“cardiac resynchronisaton” or “ cardiac pacing”):TI,AB,KY1050
#23 MESH DESCRIPTOR Oligonucleotides, Antisense EXPLODE ALL TREES50
#24 MESH DESCRIPTOR morpholines EXPLODE ALL TREES1900
#25 cardiomyopathy or cardiac NEAR failure or cardiac NEAR protection or inotropic NEAR agent or diuretic7996
#26 (cardiac NEAR therapy or ataluren or ptc124 or antisense NEAR oligonucleotide or morpholino):TI,AB,KY3173
#27 #9 or #10 OR #11 OR #12 OR #13 OR #14 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR
#25 OR #25 or #2638015
#28 #8 AND #2764
Appendix 3. MEDLINE OvidSP search strategy
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid MEDLINE(R) <1946 to Present>
Ovid MEDLINE(R) Daily Update October 13, 2017
Search Strategy:
--------------------------------------------------------------------------------
1 randomized controlled trial.pt. (496904)
2 controlled clinical trial.pt. (99253)
3 randomized.ab. (433409)
4 placebo.ab. (202740)
5 drug therapy.fs. (2114500)
6 randomly.ab. (298737)
7 trial.ab. (457112)
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8 groups.ab. (1845391)
9 or/1-8 (4369043)
10 exp animals/ not humans.sh. (4677556)
11 9 not 10 (3778961)
12 muscular dystrophies/ or muscular dystrophy, duchenne/ (19216)
13 (duchenne adj5 dystroph$).tw. (10171)
14 (becker adj5 dystroph$).tw. (1966)
15 dystrophinopath$.mp. (657)
16 dystrophin/ge (3234)
17 xldcm.tw. (9)
18 x linked dilated cardiomyopathy.tw. (81)
19 or/12-18 (22625)
20 cardiomyopathies/ or cardiomyopathy, dilated/ (42029)
21 heart failure, congestive/ or myocardial diseases/ (134371)
22 Heart Failure/ (110151)
23 cardiac protection.mp. (734)
24 ventricular dilation.mp. (1667)
25 exp Angiotensin-Converting Enzyme Inhibitors/ (44109)
26 exp Calcium Channel Blockers/ (83899)
27 exp Adrenergic beta-Antagonists/ (87190)
28 exp Cardiotonic Agents/ (212589)
29 exp Diuretics/ (81986)
30 Heart Transplantation/ (33069)
31 Pacemaker, Artificial/ (26148)
32 defibrillators/ or defibrillators, implantable/ (17140)
33 Electric Countershock/ (14690)
34 cardiac resynchronisation.mp. (550)
35 Cardiac Pacing, Artificial/ (21708)
36 exp Oligonucleotides, Antisense/ (15589)
37 exp Morpholines/ (24191)
38 (cardiomyopath$ or (cardiac adj1 failure) or (cardiac adj1 protection) or (inotropic adj1 agent$1) or diuretic$1 or (cardiac adj1
transplant$)).tw. (123920)
39 (pacemaker or (resynchronisation adj1 therap$) or ataluren or ptc124 or (antisense adj1 oligonucleotid$) ormorpholino).tw. (46306)
40 or/20-39 (770455)
41 11 and 19 and 40 (367)
42 remove duplicates from 41 (308)
Appendix 4. Embase (OvidSP) search strategy
Database: Embase <1980 to 2017 Week 41>
Search Strategy:
--------------------------------------------------------------------------------
1 crossover-procedure/ (53437)
2 double-blind procedure/ (140776)
3 randomized controlled trial/ (471914)
4 single-blind procedure/ (29732)
5 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind$) or (singl$ adj blind$) or assign$
or allocat$ or volunteer$).tw. (1803990)
6 or/1-5 (1895784)
7 exp animals/ (23302688)
8 exp humans/ (18903668)
9 7 not (7 and 8) (4399020)
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10 6 not 9 (1711898)
11 limit 10 to (conference abstracts or embase) (1434393)
12 muscular dystrophy/ or becker muscular dystrophy/ or duchenne muscular dystrophy/ or dystrophinopathy/ (27272)
13 (xldcm or x linked dilated cardiomyopathy).tw. (85)
14 (duchenne adj5 dystroph$).tw. (11864)
15 (becker adj5 dystroph$).tw. (2220)
16 dystrophinopath$.mp. (927)
17 dystrophin/ (8504)
18 or/12-17 (30754)
19 cardiomyopathy/ or congestive cardiomyopathy/ (71089)
20 congestive heart failure/ or heart failure/ (257647)
21 myocardial disease/ (5396)
22 heart protection/ (37518)
23 heart dilatation/ (6591)
24 (cardiac protection or ventricular dilation or heart failure or cardiac failure or ventricular dilation or cardiomyopath$).mp. (410670)
25 exp dipeptidyl carboxypeptidase inhibitor/ (158301)
26 exp calcium channel blocking agent/ (203204)
27 exp beta adrenergic receptor blocking agent/ (252354)
28 inotropic agent/ (11044)
29 diuretic agent/ (71583)
30 heart transplantation/ (47005)
31 sinus node/ (7754)
32 defibrillator/ (22735)
33 cardiac resynchronization therapy/ (15287)
34 ataluren/ (504)
35 antisense oligonucleotide/ (16745)
36 (avi or morpholino).mp. (24308)
37 (cardiomyopath$ or (cardiac adj1 failure) or (cardiac adj1 protection) or (inotropic adj1 agent$1) or diuretic$1 or (cardiac adj1 trans-
plant$) or pacemaker or (resynchronisation adj1 therap$) or ataluren or ptc124 or (antisense adj1 oligonucleotid$) or morpholino).tw.
(214658)
38 or/19-37 (1014796)
39 11 and 18 and 38 (192)
40 remove duplicates from 39 (184)
Appendix 5. US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov search
strategy
Advanced search
Condition or disease: muscular dystrophy
Other terms: heart
Applied filter: interventional
72Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated
cardiomyopathy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 6. World Health Organization International Clinical Trials Registry Platform search
strategy
Duchenne AND heart OR Becker AND heart OR dystrophy AND heart
H I S T O R Y
Protocol first published: Issue 4, 2011
Review first published: Issue 10, 2018
Date Event Description
10 May 2012 New citation required and minor changes New author added, one author withdrew.
10 April 2012 Amended Change to the protocol title
Minor revisions made to the objective, types of interventions, types of
studies and outcomes. A statement that we will analyse each type of
intervention separately has been included
Embase and CENTRAL search strategies added.
C O N T R I B U T I O N S O F A U T H O R S
All three authors reviewed and agreed on inclusion criteria and studies for inclusion. RQ and JB prepared the manuscript. BT prepared
the data extraction forms and completed the tables. All three authors agreed the contents of the manuscript prior to publication.
D E C L A R A T I O N S O F I N T E R E S T
John Bourke is a Consultant cardiologist and principal investigator for a multicentre, placebo-controlled trial for cardiac protection in
DMD
Teofila Bueser is a specialist nurse and manages patients with DMD, BMD and X-linked muscular dystrophy. She has no conflicts of
interest.
Dr Quinlivan has received honoraria from PTC bio for teaching on ataluren and Santhera for teaching on idebenone. She is Joint Co-
ordinating Editor of Cochrane Neuromuscular. She was not involved in the editorial process for this review.
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Internal sources
• None, Other.
External sources
• None, Other.
• National Institute of Health Research (NIHR), UK.
Ros Quinlivan is Joint Co-ordinating Editor of Cochrane Neuromuscular, the position is funded by the National Institute for Health
Research via Cochrane Infrastructure funding to Cochrane Neuromuscular
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Where trials reported multiple time points over the 6 months specified we reported the longest time point.
We further clarified our outcomes for inclusion in the ’Summary of findings’ table, deciding to report ejection fraction or fractional
shortening as measures of cardiac improvement as these are most widely understood and used (Quinlivan 2011 (amended); Quinlivan
2012).
We included a PRISMA flow chart to illustrate the study selection process.
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